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Position statement: The International Society of Sports Nutrition (ISSN) provides an objective and critical review of
the mechanisms and use of probiotic supplementation to optimize the health, performance, and recovery of
athletes. Based on the current available literature, the conclusions of the ISSN are as follows:
1) Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on
the host (FAO/WHO).
2) Probiotic administration has been linked to a multitude of health benefits, with gut and immune health being
the most researched applications.
3) Despite the existence of shared, core mechanisms for probiotic function, health benefits of probiotics are
strain- and dose-dependent.
4) Athletes have varying gut microbiota compositions that appear to reflect the activity level of the host in
comparison to sedentary people, with the differences linked primarily to the volume of exercise and amount of
protein consumption. Whether differences in gut microbiota composition affect probiotic efficacy is unknown.
5) The main function of the gut is to digest food and absorb nutrients. In athletic populations, certain probiotics
strains can increase absorption of key nutrients such as amino acids from protein, and affect the pharmacology
and physiological properties of multiple food components.
6) Immune depression in athletes worsens with excessive training load, psychological stress, disturbed sleep, and
environmental extremes, all of which can contribute to an increased risk of respiratory tract infections. In certain
situations, including exposure to crowds, foreign travel and poor hygiene at home, and training or competition
venues, athletes’ exposure to pathogens may be elevated leading to increased rates of infections.
Approximately 70% of the immune system is located in the gut and probiotic supplementation has been
shown to promote a healthy immune response. In an athletic population, specific probiotic strains can reduce
the number of episodes, severity and duration of upper respiratory tract infections.
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7) Intense, prolonged exercise, especially in the heat, has been shown to increase gut permeability which
potentially can result in systemic toxemia. Specific probiotic strains can improve the integrity of the gut-barrier
function in athletes.
8) Administration of selected anti-inflammatory probiotic strains have been linked to improved recovery from
muscle-damaging exercise.
9) The minimal effective dose and method of administration (potency per serving, single vs. split dose, delivery
form) of a specific probiotic strain depends on validation studies for this particular strain. Products that contain
probiotics must include the genus, species, and strain of each live microorganism on its label as well as the
total estimated quantity of each probiotic strain at the end of the product’s shelf life, as measured by colony
forming units (CFU) or live cells.
10) Preclinical and early human research has shown potential probiotic benefits relevant to an athletic population
that include improved body composition and lean body mass, normalizing age-related declines in testosterone
levels, reductions in cortisol levels indicating improved responses to a physical or mental stressor, reduction of
exercise-induced lactate, and increased neurotransmitter synthesis, cognition and mood. However, these
potential benefits require validation in more rigorous human studies and in an athletic population.
Keywords: Gut-muscle-Axis, Microbiome, Microbiota, Sport performance, MuscleIntroduction
The term probiotic is derived from the Latin preposition
“pro,” which means “for” and the Greek word “biotic” mean-
ing “life”. Probiotics are widely considered to be health-
promoting microorganisms. As outlined in Table 1 and as
defined by the World Gastroenterology Organization
(WGO), various ingredients can function in probiotic, pre-
biotic, and symbiotic roles. The Food and Agriculture
Organization of the United Nations (FAO) and the World
Health Organization (WHO) defines probiotics as “live mi-
croorganisms that, when administered in adequate amounts,
confer a health benefit on the host” [1]. Additionally, the
International Olympic Committee (IOC) has stated that,
“Probiotics are live micro-organisms that when administered
orally for several weeks can increase the numbers of benefi-
cial bacteria in the gut. These have been associated with a
range of potential benefits to gut health, as well as modula-
tion of immune function” [5]. Unique in comparison to
other dietary supplements, probiotic preparations contain
live, viable, defined microorganisms in sufficient numbers to
provide beneficial health effects [6]. Table 1 provides an
overview of common definitions and classifications related
to probiotic research.
The probiotic principle dates back to over 100 years ago.
In 1908, Elie Metchnikoff [7] suggested that it would be
possible to modify the microbiota in our bodies and replace
harmful microbes with useful microbes. Reported health
benefits of probiotics include modulation of the immune
response, maintenance of the intestinal barrier, antagonism
of pathogen adhesion to host tissue, and production of dif-
ferent metabolites such as vitamins, short-chain fatty acids
(SCFAs), and molecules that act as neurotransmitters in-
volved in gut–brain axis communication [8]. In the lastseveral decades, research in the area of probiotics has pro-
gressed considerably and significant advances have been
made in the selection and characterization of specific pro-
biotic cultures. A growing number of dietary supplements
containing probiotics are commercially available worldwide,
and the number of products being marketed to improve
the health and performance of athletes continues to in-
crease substantially. To appropriately describe a probiotic,
the genus, species, and strain of each live microorganism
(see Table 2) must be detailed on a product label. Addition-
ally, the product label should include the total estimated
quantity of each probiotic strain at the end of the product’s
shelf life, as measured by colony forming units (CFU) or
live cells. Moreover, only a 70% DNA-DNA reassociation is
needed for strains to be regarded as the same species [9].
The difference between a Homo sapiens and its most
closely related species, the chimpanzee (Pan troglodytes) is
98.4%. Reassociation rates of humans with other primates
like Gorilla (97.7%), Orangutan (96.5%), Siamang gibbon
(95.5%), and the Hamadras baboon (92.7%) are also rela-
tively high. Further, Lemur (78%) are still within the range
for probiotics to be considered the same species (see Fig. 1).
Analyzing potential health benefits of probiotics must occur
on a strain level, and consumption of probiotic products
only disclosing genus and species, but not the strain, on the
label should be discouraged.
Probiotics are available commercially in capsule or
tablet forms, as powder sachets, in the form of liquids
and in specific foods such as yogurt and nutrition bars.
While fermented foods, such as sauerkraut or kimchi,
contain live microbes, they are currently not classified as
probiotics, as those products have not been sufficiently
studied for their health benefit as stipulated by the
Table 1 Definitions of common terminology and classifications in probiotic research
Concept Definition
Probiotics Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host [1].
Prebiotic A substrate that is selectively utilized by host microorganisms conferring a health benefit on the host [2].
Synbiotics A synbiotic product beneficially affects the host in improving the survival and implantation of live microbial dietary
supplements in the gastrointestinal tract by selectively stimulating the growth and/or activating the metabolism of
one or a limited number of health-promoting bacteria [3].
Postbiotics Postbiotics are bioactive components produced by beneficial bacteria (through a natural fermentation process) which
have biological activity in the gut (e.g. short-chain fatty acids) [4].
Immunobiotics Inactivated probiotics (e.g. heat-killed), in which the dead cells maintain their immune benefit.
Gut The gastrointestinal tract is a long tube that starts in the mouth and ends at the anus. Its main function is to process
food. Approximately 70% of antibody producing cells are is located in the digestive system.
Microbiota vs. Microbiome The gut microbiota is a diverse ecosystem consisting of bacteria, archaea, viruses, protists and fungal communities
(mycobiome) living in the human gut. Microbiome refers to the collection of genomes from all microorganisms in
a particular environment
Transient vs. Resident Strain Supplementary probiotics are transient strains. There is currently no evidence that supplementary probiotics can
permanently colonize in the gut as resident strains resist colonization by transient strains. Transient probiotics
strains may have numerous beneficial health effects by positively interacting with the immune system or
stimulating growth of beneficial resident strains.
Alpha-Diversity Represents the number of species and the proportion in which each species is represented in the microbiota. A
high alpha diversity is present when there is a high number of species and their quantities are alike.
Beta-Diversity Beta-diversity broadly reflects the species composition diversity between regional and local sites. The beta diversity
measures the turnover of species between two regions in terms of gain or loss of species
Classes of probiotics Definition
Lactic acid bacteria (LAB) Nonpathogenic, nontoxigenic, Gram-positive, fermentative bacteria that are associated with the production of lactic
acid from carbohydrates. LAB grow anaerobically, but unlike other anaerobes, most can grow in the presence of
oxygen. Examples include Lactobacillus (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri),
Streptococcus (e.g. salivarius, thermophilus) and Lactococcus.
Bifidobacteria Bifidobacteria are among the first microbes to colonize the human gastrointestinal tract. Examples include
Bifidobacterium bifidum, longum, animalis, and breve. Bifidobacteria are not LAB. They are, however lactic acid
producing bacteria (but through a very different metabolic pathway).
Spore-forming bacteria Soil-based probiotics, also referred to endospores, are the dormant form of bacteria that are highly resistant to
physical and chemical influences. Upon ingestion, these spores have a high survival rate through the stomach
and germinate in the small intestine. Examples include Bacillus (e.g. coagulans, subtilis). Spore forming bacteria
are not necessarily of soil origin. They can also be found in fermented foods.
Yeast Examples include Saccharomyces boulardii.
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facture and shelf-life limit food and supplement delivery
forms. Probiotics exhibit strain-specific differences in
their ability to colonize the gastrointestinal (GI) tract,
clinical efficacy, and the type and magnitude of benefits
to health in a range of different population cohorts [10].
The effects of probiotics in athletes have been less de-
scribed in comparison to animal studies and human
clinical conditions in the general population. However,
the body of probiotic research in recreational and com-
petitive athletes is expanding, including investigations in
GI health, exercise performance, recovery, physical fa-
tigue, immunity, and body composition.
Role of diet and exercise on an athlete’s gut microbiome
Numerous factors such as age, genetics, drug use, stress,
smoking, and especially diet can all affect the gut micro-
biome, influencing a complex ecosystem that is highly dy-
namic and individual [11–14]. In relation, physical activityhas been an area of growing interest in gut micro-
biome research and appears to promote a health-
associated microbiota. In the context of athletes, the
present body of literature suggests their microbiota has
several key differences in comparison to other popula-
tions, likely driven, in part, by exercise and diet. Indeed,
several observational studies have investigated the differ-
ence in the composition of the gut microbiota between
those who are highly physically active (including athletes)
and a range of other populations. Reported results include
that a higher abundance of health-promoting bacterial
species [15–17], increased microbiome diversity [16, 18],
and greater relative increases in metabolic pathways (e.g.
amino acid and antibiotic biosynthesis and carbohydrate
metabolism) and fecal metabolites (e.g. microbial pro-
duced SCFAs; acetate, propionate, and butyrate) are asso-
ciated with enhanced fitness [17, 19].
The current evidence supports the role of exercise as an
important behavioral factor that can affect qualitative and
Table 2 Example illustrating the names of a bacterium (L.
rhamnosus GG) at different taxonomic levels
Taxonomic level Name
Domain Bacteria
Phylum Firmicutes
Class Bacilli
Order Lactobacillales
Family Lactobacillaceae
Genus Lactobacillus
Species Lactobacillus rhamnosus
Strain Lactobacillus rhamnosus GG
Jäger et al. Journal of the International Society of Sports Nutrition           (2019) 16:62 Page 4 of 44quantitative changes in the gut microbial composition with
benefit to the host. Exercise appears to be able to en-
rich microbiota diversity [20–25], increase the Bacter-
oidetes-Firmicutes ratio [23], stimulate the
proliferation of bacteria which can modulate mucosal
immunity [26], improve barrier functions [27], andFig. 1 Probiotic benefits are strain specific and probiotics must be describe
genus and species can be as significant as the difference between a humastimulate bacteria capable of producing substances
that protect against GI disorders [28, 29]. Recent re-
search provides further evidence for a role of exercise
in shaping the microbiome, with elite runners having
a greater abundance of Veillonella that appears to
confer a metabolic advantage for endurance exercise
by converting exercise-induced lactate to propionate.
Pre-clinical studies with Veillonella show a 13% in-
crease in endurance performance [30]. It is likely that
the diverse, metabolically favorable intestinal micro-
biome evident in the elite athlete is the cumulative
manifestation of many years of high nutrient intake
and high degrees of physical activity and training
throughout youth, adolescence and during adult par-
ticipation in professional sports [31].
In researching the human gut microbiota, it is diffi-
cult to examine exercise and diet separately as this
relationship is compounded by changes in dietary in-
takes that often are associated with physical activity
(e.g., increased protein intake in resistance trained
athletes or carbohydrate intake in endurance athletesd as genus, species and strain, as genetic variation between the same
n and a lemur (illustration by Stephen Somers, Milwaukee, WI, USA)
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eral). Furthermore, comparing the microbiota of non-
athletes to athletes and ascribing any observed differ-
ences to exercise alone is not advisable. Athletes gen-
erally consume a diet that differs from the general
population that has implications for the composition
of the gut microbiome.
Diet is an established modulator of gut microbiota
composition, with significant change reported within
24 h of a dietary modification [32]. Various food com-
ponents, dietary patterns, and nutrients all have the
potential to alter considerably the growth of different
gut microbial populations. Partitioning of individuals
into enterotypes appears to be driven by whether
their primary dietary patterns include high complex
carbohydrate (Prevotella) or high fat/protein (Bacter-
oides) consumption [33]. Protein intake appears to be
a strong modulator of the microbiota [20, 32, 34],
with whey protein showing some potential benefits
that need further study in humans [31, 35]. Carbohy-
drates are well known for their profound effect on
the gut microbiota, with increased intake of dietary
fiber associated with microbial richness and/or diver-
sity [36, 37]. In athletes, higher intakes of carbohy-
drates and dietary fiber appear to be associated with
increased abundance of Prevotella [17, 38]. The spe-
cific effects of fat on the gut microbiota is difficult to
isolate, however, the types of fats consumed appear to
be important [39]. Increased fat intake may promote
higher concentrations of bile-tolerant bacteria (pre-
sumably because an extremely high fat intake is
known to increase bile acid secretion) [32]. Further
research is needed to determine the synthesis kinetics
and clinical consequence of bile acids and their by-
products during increased nutritional intake and
metabolic demands during exercise.
Based on the current body of evidence, the athlete
gut microbiome may possess a functional capacity
that is primed for tissue repair and a greater ability
to harness energy from the diet with increased cap-
acity for carbohydrate, cell structure, and nucleotide
biosynthesis [19]. This assertion reflects the signifi-
cant energy demands and tissue adaptation that oc-
curs during intense exercise and elite sport. It
appears that being physically active is another im-
portant factor in the relationship between the micro-
biota and host metabolism. Intervention-based
studies to delineate this relationship will be import-
ant and may provide further insights into optimal
therapies to influence the gut microbiota, and its re-
lationship with health and disease as well as athletic
performance. Fig. 2 illustrates that an athlete’s gut
microbiota is different from a sedentary individual
with increased diversity and greater abundance ofhealth promoting bacterial species linked to exercise
and increased protein intake.
Key Points 1 – Role of diet and exercise on an athlete’s gut
microbiome.
• Active individuals appear to display a higher abundance of health-
promoting bacterial species and increased microbiota diversity.
• Body composition and physical activity are positively correlated with
several bacterial populations.
• Overall exercise can enrich the microbiota diversity, increase the
Bacteroidetes-Firmicutes ratio, stimulate the proliferation of bacteria
which can modulate mucosal immunity, and improve barrier
functions.
• Diet is an established modulator of gut microbiota composition and
activity, with marked changes in microbiota composition evident
within 24 h of a dietary modification.
• Protein intake appears to be a strong modulator of microbiota
diversity, with whey protein showing some potential benefits that
need further study in humans.
• Higher intakes of carbohydrate and dietary fiber in athletes appear
to be associated with increased abundance of Prevotella.
• The specific effects of fat on the gut microbiota is difficult to isolate,
however, the types of fats consumed appear to be important.Benefits of probiotic supplementation in athletes
Strenuous and prolonged exercise places stress on the
GI tract that increases the likelihood of multiple
symptoms associated with a disturbed gut microbiota
and decreased performance [40], including abdominal
cramping, acid reflux (heartburn), nausea, vomiting,
diarrhea, and permeability of the gut that may
precipitate systemic endotoxemia [41]. As a major
gateway for pathogen entry, the GI tract is heavily
protected by the immune system. Modulation of the
immune system to increase defenses against upper
respiratory tract infection (URTI) is the potential benefit
of probiotics for athletes that has been most extensively
researched [40]. The microbiome may also have indirect
functional influence on various indices of exercise
performance and recovery [42–46]. Therefore, probiotics
as functional modulators of the microbiome can
potentially promote health, exercise adaptation, and
performance in athletes.
Probiotics may regulate the mucosal immune response
[47], improve the activity of macrophages [48] and
modulate the expression of the genes associated with
macrophage activity. Probiotics may also interact with
Toll-like receptors (TLRs) and downregulate the
expression of nuclear factor (NF)-κB and pro-
inflammatory cytokines [49, 50]. Additionally, levels of
anti-inflammatory cytokines and immunoglobulins, im-
mune cell proliferation, and production of pro-
inflammatory cytokines by T cells may be modulated fol-
lowing probiotic supplementation [51, 52]. However, it
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competition, and a wide range of interactions between
diet, physical activity and other lifestyle stresses needs to
be considered. Understanding whether probiotics play a
role in athletic performance is of particular interest to
athletes who work to improve their results in competi-
tion as well as reduce recovery time during training.
Moreover, this knowledge may be relevant and of direct
benefit to general human health.
The study of probiotic supplementation in athletes
and physically active individuals is quite new with the
first study in humans published by Clancy et al. [53].
Over the last 13 years, the popularity and number of
publications has increased substantially (see Table 3).
The number of products containing probiotics directed
towards those that exercise is increasing.
The effect of probiotic supplementation on performance
Research specifically designed to investigate the effect of
probiotic supplementation on performance has been lessFig. 2 Early research indicates that gut bacteria reflect the activity level of
individual: increased diversity and greater abundance of health promoting
(illustration by Stephen Somers, Milwaukee, WI, USA)common and overall the results are mixed. Earlier
studies that reported performance outcomes generally
had primary aims related to immunity and GI health. Of
the 24 studies that assessed some metric of athletic
performance, 17 reported a null effect, while 7 reported
significant improvement. However, more recent research
indicates that probiotic supplementation can promote
improvements in exercise performance through various
pathways in athletes and physically active individuals
using discrete strains of probiotics.
Some studies have used single probiotic strain
interventions. For example, in a 16-week study investi-
gating the effect of Lactobacillus fermentum VRI-003 on
the immunity in 20 elite male distance runners, mea-
sures of performance (which included training duration,
intensity, and VO2 max) did not change significantly
[57]. Similarly, in 80 competitive cyclists, 11 weeks of
supplementation with L. fermentum (PCC®) had no effect
on peak power or VO2 max [61]. Four weeks of supple-
mentation with Lactobacillus gasseri OLL2809 andits host. An athlete’s gut microbiota is different from a sedentary
bacterial species linked to exercise and increased protein intake
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not improve cycle ergometer performance [67]. Gill
et al. [75] did not find a difference in perception of effort
during a treadmill test in eight male endurance-trained
runners who supplemented with a high-dose of Lactoba-
cillus casei (10 × 1010 CFU). Finally, in 39 elite athletes
from various sports, 14 weeks of Lactobacillus helveticus
Lafti L10 supplementation during the winter did not
elicit significant differences in exercise performance as
measured by VO2 max, treadmill performance time,
maximal heart rate and heart rate recovery [79]. The sin-
gle strain interventions used in these five studies did not
produce an aerobic performance benefit.
Null findings were similarly reported in several studies
investigating the effects of multi-strain probiotics on aer-
obic performance. For instance, in endurance-trained
men, 14 weeks of a multi-species probiotic had no effect
on VO2 max and maximum performance [63]. In a study
designed to determine the effects of a 30-day period of
supplementation with a 14-strain probiotic at rest, and in
response to an acute bout of prolonged cycling exercise
for 2 h at 60% VO2max in 11 active, healthy adults there
was no significant change in rating of perceived exertion
and heart rate [73]. In another study assessing the effects
of a multi-strain probiotic (along with 55.8mg fructooli-
gosaccharides, 400mg alpha-lipoic acid, 600mgN-acetyl-
carnitine) in 30 recreational athletes over 12 weeks of pro-
gressive triathlon training no significant differences were
found in race times [77]. Marshall et al. [81] investigated
the effects of a multi-strain probiotic for 12 weeks of
marathon training in a group of 32 marathon competitors
and found no difference in marathon time to completion
compared to the control group.
However positive results were reported in thirty
endurance athletes supplementing with a yogurt drink,
either containing Streptococcus thermophilus or Lactoba
cillus delbrueckii ssp. bulgaricus or no probiotics over 30
days during intense aerobic training. There was a
significant increase in VO2max and aerobic power in the
Cooper aerobic test [45]. In thirty-three trained athletes,
12 weeks of winter training supplementation with a multi-
species probiotic did not benefit athletic performance;
however, the training load (hours per week) was higher in
those who supplemented with the probiotic blend vs. the
placebo group [78]. One explanation for these findings
could be that probiotics may enable better performance
capabilities and training adherence when the risk of URTI
development is reduced, as individuals with fewer episodes
of infections such as common colds are able to train more
often and harder. Further, Strasser et al. [78], noted that
the multi-species probiotic limited exercise-induced
reductions in circulating tryptophan concentration.
Higher serum tryptophan levels may enhance the
tryptophan transport into the brain and supportserotonin metabolism, which can influence an individ-
ual’s sensation of fatigue and thus potentially affect
training adherence and performance [91]. Interest-
ingly, VO2max was positively correlated with pre-
exercise serum tryptophan levels at a moderate mag-
nitude, supporting a role of tryptophan metabolism in
training performance.
Huang et al. [85], found increased endurance
performance and elevated blood glucose concentration
following exercise-to-exhaustion after 6 weeks of high
dose (1 × 1011 CFU) Lactobacillus plantarum TWK10 (a
plant Lactobacillus strain isolated from Taiwanese
pickled vegetables) supplementation in healthy male
adults. However, as these were untrained males and
no aerobic exercise intervention was reported in this
study, these data should be interpreted conservatively
in relation to endurance athletes. These results might
be explained by an anti-inflammatory effect from L.
plantarum TWK10 [92] on skeletal muscle and im-
provement in energy harvest, possibly related to
glycogenesis regulation for exercise demand. Interest-
ingly, L. plantarum KX041 can maintain intestinal
permeability and exert antioxidant capacity [93].
Moreover, certain strains of L. plantarum activate cell
growth signaling pathways in gut enterocytes which
in turn increases protein metabolism in the gut [94].
Further, L. plantarum can rescue the shunted growth
phenotype in malnourished mice by activating muscle,
bone, and organ growth [95].
In a study investigating the effect of a multi-strain pro-
biotic yogurt on performance in adolescent female endur-
ance swimmers over 8 weeks, there was a significant
improvement in VO2 max [44]. The improvement in VO2
max was attributed to the reduction in number and dur-
ation of URTI for athletes following intake of the multi-
strain probiotic yogurt. In another study researching the ef-
fect of multi-strain probiotics Shing et al. [46] found 4
weeks of supplementation improved time to fatigue while
running in the heat for ten male runners. While the mech-
anism for improvement was unclear, it was speculated that
probiotics may exert small to large effects on GI structural
integrity, endotoxin translocation and immune modulation
that combine to enhance exercise performance. In contrast,
a Kefir beverage (a naturally fermented milk beverage con-
taining a defined mixed microbial culture of lactic acid bac-
teria and yeasts) consumed over 15 weeks of marathon
training by sixty-seven male and female runners had no ef-
fect on 1.5 mile run test performance [74]. Currently, there
are more studies showing a benefit for multi-strain probio-
tics in relation to performance measures compared to
single-strain probiotics. While there are some encouraging
results, a large majority of studies have found no effect on
aerobic performance. It appears that some of the positive
benefits of probiotic supplementation may be indirect by
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However, additional research is warranted including inves-
tigating potential performance outcomes beyond aerobic-
based endurance exercise.
Other studies have explored the effect of probiotic
supplementation in relation to resistance training on muscle
recovery and body composition. A pilot study in ten
subjects using resistance trained males supplemented 20 g
of casein protein with or without Bacillus coagulans GBI-
30, 6086 (BC30) for 8 weeks following a periodized resist-
ance training program showed a trend to increase vertical
jump power [71]. Jäger et al. [43] speculated that the poten-
tial improvement in vertical jump performance may have
been related to improved muscle recovery through gut mi-
crobial modulation. In a follow up study, 20 g of casein pro-
tein co-administered with B. coagulans GBI-30, 6086
(BC30) or a placebo in recreationally-trained individuals for
2 weeks increased recovery and decreased soreness after a
muscle-damaging single-leg training bout [43]. Further-
more, exercise-induced muscle damage was decreased as
measured by serum creatine kinase, which may also indicate
improved cellular integrity rather than damage per se. While
not fully understood, candidate mechanisms of action in-
cluded the production of digestive enzymes that are active
under gut conditions (e.g. alkaline proteases) and these pro-
teases can digest proteins more efficiently than the en-
dogenous human proteases alone [43, 96, 97]. Further, B.
coagulans GBI-30, 6086 enhances the health of the cells of
the gut lining through improved nutrient absorption includ-
ing minerals, peptides, and amino acids by decreasing in-
flammation and encouraging optimum development of the
absorptive area of the villi [98]. In vitro, B. coagulans GBI-
30, 6086 can increase protein absorption [99]. The combin-
ation of B. coagulans GBI-30, 6086 with casein protein may
have acted synergistically to augment digestion and modu-
late absorption.
In fifteen resistance-trained men, 3 weeks of Bifidobacter-
ium breve BR03 and S. thermophilus FP4 supplementation
improved isometric mean peak torque production and
range-of-motion during acute recovery after a muscle-
damaging elbow flexor exercise challenge in comparison to
a control group [42]. While mechanisms behind these ob-
servations were not described, these strains can have anti-
inflammatory effects [100–102] and colonize in different
areas of the GI tract. However, using the same strains and
dose, Antonio et al. [84], failed to see a significant effect on
body composition in highly-trained men and women over a
longer, six-week period. In both of the above studies partici-
pants were not provided supplemental protein. Toohey
et al. [103] investigated the effects of Bacillus subtilis DE111
probiotic supplementation on muscle thickness and
strength, body composition, and athletic performance in
Division I female volleyball and soccer athletes for 10 weeks
of an offseason resistance training program. Both groupsconsumed a protein and carbohydrate recovery drink
(consisting of 45 g carbohydrates, 20 g protein, and 2 g fat)
immediately after each training session. Probiotic sup-
plementation with the post-workout recovery drink
yielded greater reductions in body fat and increases in
fat free mass after 10 weeks of resistance training
than a placebo. Although no performance advantages
were observed, Toohey et al. [103], speculated that
supplementation may have promoted improved dietary
protein absorption and utilization, contributing to im-
provements in body composition by increasing dietary
protein-induced thermogenesis and altering satiety
signaling. It seems that several strains of lactic acid
bacteria, including L. gasseri SBT 2055, Lactobacillus
rhamnosus ATCC 53103, and the combination of L.
rhamnosus ATCC 53102 and Bifidobacterium lactis
Bb12, are effective at reducing fat mass in obese
humans [104]. Additionally, other strains of B. breve
have shown anti-obesity effects in both humans [105]
and mice [106].
Townsend et al. [83], evaluated the effect daily B.
subtilis (DE111) supplementation on physical and
performance adaptations in Division I collegiate
baseball players following 12 weeks of offseason
resistance training. On training days, placebo or
probiotic capsules were consumed immediately post-
workout with a protein and carbohydrate recovery
drink (consisting of 36 g carbohydrates, 27 g protein,
and 2 g fat). There were no group differences ob-
served between those who took the probiotic and pla-
cebo for any measure of strength, performance, or
body composition. However, those athletes who did
supplement with probiotics had significantly lower
serum TNF-α concentrations than the placebo group.
Elevations in TNF-α have been linked to suppressed
protein synthesis, disordered sleep, and impaired mus-
cular performance [107–109]. The null performance
findings reported by Townsend et al. [83] and Anto-
nio et al. [84] may have been the result of an inability
for the probiotic supplement to modify healthy partic-
ipants’ microbiomes. Indeed, the subjects in these two
studies were young, healthy and highly active. In this
regard, systematic reviews [110, 111] and an original
investigation involving supplementation [112] of pro-
biotic supplementation in adults indicate that pro-
biotic supplementation is more likely to alter the
microbiome composition of dysregulated microbiomes
compared to healthy ones. While probiotic consump-
tion may not alter microbiome composition, it can
alter functionality by up regulation of gene expression
and metabolic pathways. As noted for aerobic per-
formance, it is also plausible that probiotic supple-
mentation confers an indirect effect on performance
and that the training, diet, and recovery of the
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enough to mask any small additional benefits.
Key Points 2 – Probiotic Supplementation and Performance
• To date single-strain probiotic supplementation has produced a sig-
nificant aerobic performance benefit in only one study.
• Supplementation with multi-strain probiotics has been reported to
increase VO2 max, aerobic power, training load, and time to exhaus-
tion in several studies, but more studies have not found such an
effect.
• In response to muscle-damaging resistance exercise, probiotic sup-
plementation (paired with protein) can expedite recovery and de-
crease soreness and other indices of skeletal muscle damage.
• The effect of probiotic supplementation on body composition has
been mixed and requires further research.
• Probiotics supplementation as an ergogenic aid for performance
enhancement requires further investigation and may be indirect via
modulation of other systems.The effect of probiotic supplementation on the immune
system
The mucosal lining of the GI tract represents the first-
line-of-defense against invading pathogens and is an im-
portant interface with the host immune system. Exhaust-
ive physical exercise negatively impacts immunity,
reducing of the count and function of immune cells, such
as natural killer (NK) cells and T lymphocytes. Pro-
inflammatory cytokines such as IL-1, TNF-α and IFN-γ
generally remain unchanged after prolonged exercise
whereas the inflammation-responsive cytokine IL-6 and
anti-inflammatory cytokines such as IL-10, IL-1ra, sTNFR
increase markedly. The increase in IL-6 is not solely in re-
sponse to inflammation in this situation as it also origi-
nates from contracting muscle and is associated with
glycogen regulation. Gene expression in white blood cells
is upregulated for most anti-inflammatory markers and
downregulated for pro-inflammatory markers and TLR
signaling. The anti-inflammatory hormone cortisol is also
elevated [53, 57, 59, 113, 114]. Changes in immune health
are associated with increased incidence of URTIs and dis-
orders of the GI tract [46, 53] which have the potential to
impair physical performance and/or cause an athlete to
miss training or competition [115]. These conditions usu-
ally occur during competitive periods that are commonly
represented by higher intensities and greater volumes of
exercise [116], affecting the athlete’s health and impairing
physical performance when needed most [115]. In this
context, interventions that prevent or mitigate these con-
ditions can indirectly improve physical and competition
performance. Among the nutritional supplements used in
modulation of the immune response of athletes, probiotics
are noteworthy [92].
Probiotics appear to augment intestinal communication
between the host immune system and commensal bacteriato establish mutualistic benefits. The roles of microbial-
derived SCFAs, particularly butyric acid in the colon, are
important in mucosal homeostasis through regulation of
epithelial turnover and induction of regulatory T (Treg)
cells [117]. Beyond the GI tract, probiotics have an immu-
nomodulatory effect through the common mucosal im-
mune system, in which cells from inductive sites (e.g.,
Peyer’s Patches in the intestines) translocate to mucosal
surfaces following interaction with antigen-presenting
cells [118].
Research investigating the effects of probiotics on
immune outcomes have been the most prevalent type of
research in athletic populations. Of the 22 studies
reviewed in this Position Stand that assessed the effect
of probiotics on outcomes related to the immune
system, 14 reported significant improvement, whereas 8
reported no effects.
Of particular relevance to athletes is the reduction in
incidence and/or severity of symptoms from illnesses like
URTI. In a large study of 465 active individuals who had a
normal activity load of approximately 6 h per week, West
et al. [68] compared a single strain treatment consisting of
Bifidobacterium animalis ssp. lactis Bl-04 and double-
strain probiotic consisting of Lactobacillus acidophilus
NCFM and B. animalis subsp. lactis Bi-07 to placebo over
a 150-day intervention. Daily B. animalis ssp. lactis Bl-04
supplementation for 150 days was associated with a 27%
reduction in the risk of any URTI episode compared to
placebo supplementation. Supplementation with the
double-strain probiotic resulted in a 19% decrease of
URTI risk, although this was not statistically significant.
Moreover, both probiotic supplement groups exhibited a
~ 0.8-month delay in time to illness. Importantly, healthy
active individuals with a lighter training load, and presum-
ably at a lower risk for URTIs, also appeared to benefit
from a probiotic supplement.
The majority of studies that have investigated the
potential benefits of probiotics on URTIs have been
conducted in endurance athletes with generally high
training loads. For example, Cox et al. [57] studied the
effect of L. fermentum VRI-003 (PCC) over 16 weeks of
winter training in 20 elite male distance runners on inci-
dence of illness and infection. Probiotic supplementation
significantly reduced URTI incidence and severity com-
pared to placebo. Specifically, those in the treatment group
reported less than half the number of days of respiratory ill-
ness symptoms compared to the control group during the
intervention. While not significant, there was a trend for
enhanced T-lymphocyte function, which may be in part re-
sponsible for the immunological benefits. Similarly, Gleeson
et al. [60] examined the effects of Lactobacillus casei Shir-
ota during 4 months of winter training in endurance-based
recreational athletes and observed a significant reduction in
URTIs compared to placebo. In addition, salivary IgA
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the probiotic. However, severity and duration of symptoms
were similar between the treatment and placebo groups.
Supplementation with the same strain 30 days prior to a
marathon race resulted in improved systemic and airways
immune responses, and showed a trend toward improved
incidents and duration of URTI post-marathon [90]. In
competitive cyclists, West et al. [61] reported reduced se-
verity of self-reported symptoms of lower respiratory illness
and use of cold and flu medication over an 11-week winter
training period with L. fermentum (PCC®) compared to pla-
cebo. Interestingly, this effect was only noted in males and
not females. Strasser et al. [78] examined the effect of 12
weeks of treatment with a multi-strain probiotic on the in-
cidence of URTIs and metabolism of aromatic amino acids
after exhaustive aerobic exercise in highly trained athletes
during the winter. Daily supplementation with probiotics
reduced the incidence of URTI compared to placebo. In
addition, supplementation limited exercise-induced reduc-
tions in tryptophan levels, which may reduce the risk of de-
veloping an infection.
Beyond studies investigating traditional endurance
athletes with high aerobic training loads, probiotic
supplementation has also been examined in other athletes
with varying demands. For instance, Salarkia et al. [44]
reported that 8 weeks of supplementation with a multi-
strain probiotic yogurt reduced the number of episodes of
URTIs in adolescent female swimmers compared to the
same yogurt without probiotics. Haywood et al. [69] inves-
tigated the effect of a multi-strain probiotic over 4 weeks
in 30 elite union rugby players to determine effectiveness
on the number, duration and severity of infections. The
probiotic group had lower incidence of infection-related
symptoms compared to placebo, although there was no
difference in the severity of the symptoms between the
two treatment groups. In a study of an eclectic group of
elite athletes training in badminton, triathlon, cycling, al-
pinism, athletics, karate, savate, kayak, judo, tennis, and
swimming, Michalickova et al. [79] studied the effects of
L. helveticus Lafti L10 over 14 weeks during the winter.
Athletes all had high training loads of > 11 h per week and
were winners of the national or European and world
championships in their categories and sport. Supplemen-
tation with the probiotic significantly reduced the length
of URTI episodes and lowered the number of symptoms
per episode compared to placebo. Moreover, there was a
significant increase of CD4+/CD8+ (T helper/T suppres-
sor) cells ratio in the probiotic group. Previously, this ratio
has been noted as an index sensitive to high training loads
and was decreased after strenuous physical activity [36,
119]. In addition, low CD4+/CD8+ cell ratio is usually re-
lated to acute viral diseases [120].
Several studies that assessed similar outcomes did not
report significant effects from probiotic supplementationcompared to placebo. For example, a 12-week study on
141 non-elite marathon runners during pollen season sup-
plementing daily with L. rhammnosus GG (LGG) did not
find a significant effect on allergic markers [54] or on the
incidence of UTRI episodes [55]. Similarly, there was no
significant effect on URTI incidence in a study investigat-
ing the effect of L. casei supplementation in French sol-
diers participating in intense military training for 3 weeks
in a 5-day combat course [56]. In addition, there was no
difference in salivary IgA or total and differential leukocyte
and lymphocyte subsets.
Gleeson et al. [64] examined the effects of daily
supplementation of L. salivarius on 66 endurance-based
recreational athletes during a four-month period in the
spring. There was little effect on frequency, severity or
duration of URTIs. In addition, circulating and salivary
immune markers did not change over the course of the
study and were not different between probiotic and pla-
cebo groups. Gleeson et al. [80] also assessed the effect of
L. casei Shirota on the incidence of URTIs over a 20-week
period during the winter in 243 college endurance ath-
letes. Similarly, there was no significant difference between
those that consumed the probiotic and the placebo treat-
ment. However, there was a reduction in plasma cyto-
megalovirus and Epstein Barr virus antibody titers in
seropositive athletes compared to placebo, an effect inter-
preted as a benefit to overall immune status.
While these null findings are important to consider, the
current overall body of evidence is weighted notably in
favor of probiotics on reduction of URTIs and related
symptoms. However, a central issue in relation to the effects
of probiotics on immunity, and probiotic research in
general, is the large assortment of strains used. Shared, core
mechanisms for probiotic function are evident, although
some mechanisms may be more narrowly distributed,
including those related to immunomodulation [121]. In
addition, it is important to note that immune response is
complex, as are many of the methodologies used to
measure it. For example, an immunomodulatory effect of
probiotics is attributed to the release of a large number of
cytokines and chemokines from immune cells, which can
further impact the innate and adaptive immune systems
[122]. Therefore, it is not surprising that the beneficial effect
of probiotic administration on the incidence of respiratory
illness is possibly linked enhancement of systemic and
mucosal immunity. It is possible changes occurred at this
level and were not detected in studies that only measured
URTI associated metrics. Future work in this area should
pair the investigation of URTI incidence and symptomology
with other markers of immune response to provide a more
thorough understanding of how different probiotics might
influence the immune system.
Although less common than symptom outcomes, several
studies have provided encouraging evidence in regard to
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instance, Clancy et al. [53] sought to determine if immune
variables differed between healthy and fatigued recreational
athletes after Lactobacillus intervention. One month of
daily L. acidophilus supplementation significantly increased
secretion of interferon (IFN)-γ from T cells in fatigued
athletes to levels found in healthy athletes and increased
the concentration of IFN-γ in saliva of healthy control ath-
letes. IFN-γ is a cytokine intricately linked to mechanisms
of control of both virus shedding and disease re-activation.
Sashihara et al. [67] evaluated the immunopotentiation and
fatigue-alleviation effects of L. gasseri OLL2809 supplemen-
tation for 4-weeks in 44 university-student athletes. Before
and after the treatment period, the subjects performed
strenuous cycle ergometer exercise for 1 h. The probiotic
supplementation prevented reduced NK cell activity after
strenuous exercise which may enhance resistance against
infections. In another short-term study, Aghaee et al. [70]
reported that a probiotic supplement for 30 days in 16 male
athletes increased blood monocyte levels following exhaust-
ive exercise in comparison to placebo control. In a longer
duration study, Michalickova et al. [79] investigated the ef-
fects of L. helveticus Lafti L10 supplementation on systemic
humoral and mucosal immune response in 30 elite athletes
with a high training load (> 11 h per week) over 14 weeks in
the winter. Those that consumed the probiotic exhibited at-
tenuated decreases in total salivary IgA level compared to
athletes in the placebo group. Given the fact that mucosal
surface is the first-line-of-defense against different patho-
gens, this finding might have a practical application in
terms of prevention of URTIs during strenuous exercise in
elite athletes. In comparison to some of the previous studies
that didn’t report changes in immune parameters, yet noted
a difference in URTI incidence, it is possible that in these
circumstances these strains could have displayed antagonis-
tic activities against pathogens and not direct stimulation of
the immune system. These effects could include the pro-
duction of antimicrobials, such as bacteriocins, and low
molecular weight compounds such as hydrogen peroxide,
lactic acid, and acetic acid [123–125]. These substances
could function to outcompete pathogenic bacteria and help
in easing or preventing URTI symptoms [126].
In contrast, West et al. [66] did not find significant
effects of a synbiotic product including multi-strain pro-
biotics (Lactobacillus paracasei ssp. paracasei (L. casei
431®), B. animalis ssp. lactis (BB-12®), L. acidophilus LA-
5, L. rhamnosus GG) on markers of circulating and mu-
cosal immunity in 22 recreational cyclists over a three-
week training period. In another small study of the ef-
fects of a multi-strain probiotic (L. acidophilus, L. del-
brueckii ssp. bulgaricus, Lactococcus lactis ssp. lactis, L.
casei, L. helveticus, L. plantarum, L. rhamnosus, L. sali-
varius ssp. salivarius, B. breve, Bifidobacterium bifidum,
B. infantis, Bifidobacterium longum, B. subtilis, and S.thermophilus) on mucosal immunity, Muhamad & Glee-
son [73] did not report a significant alteration in salivary
antimicrobial proteins at rest or in response to an acute
bout of prolonged exercise in 11 active, healthy adults
after 30 days of supplementation. Using a high-dose pro-
biotic treatment, Gill et al. [75] studied 8 male endur-
ance runners who consumed 10 × 1010 CFU of L. casei
for 7 days prior to a two-hour running exercise at 60%
VO2max in hot ambient conditions (34.0 °C and 32%
relative humidity). Supplementation did not enhance sal-
ivary antimicrobial proteins responses and subsequent
oral-respiratory mucosal immune status above placebo.
Finally, Carbuhn et al. [86] explored the effects of B.
longum 35,624 supplementation in 20 female Division I
collegiate swimmers during a 6-week intense training
phase on IgA. There were no difference in salivary IgA
between groups throughout the study in agreement with
a study investigating B. subtilis DE111 in collegiate base-
ball players [83].
Overall, the effect of probiotic supplementation on the
immune system in athletes is likely positive and beneficial.
Episodes of illness often occur during heavy exercise
training periods, a time when athletes obtain the greatest
improvements in fitness. Illness that interrupts individual
training sessions may prevent athletes from maximizing
the effects of their training program. Therefore,
probiotic supplementation may be viewed as a viable
dietary supplement to support immune function
during these periods.
Key Points 3 – Effects of Probiotic Supplementation on Immune
Function
• Athletes may compromise their immune status with high training
loads (over-reaching, over-training) which can increase the risk of ill-
ness such as URTIs.
• Overall, the current body of evidence indicates small variable
benefits of probiotics during intense training, particularly in
endurance athletes, the cohort where the majority of studies are
conducted.
• There is more evidence for the clinical effects of probiotics reducing
the incidence URTI and related illness.
• Positive changes in circulating and salivary immune markers have
been more variable and require further research to define more
clearly.The effect of probiotic supplementation on GI tract health
GI problems often occur in endurance athletes and
particularly during prolonged events such as cycling,
triathlons and marathons [41, 127]. Symptoms such as
nausea, cramping, bloating, and diarrhea most likely
reflect redistribution of blood flow from the gut to the
skin for cooling purposes. Exercise-induced redistribution
of blood can result in splanchnic hypoperfusion as a pos-
sible mechanism for gut dysfunction [128, 129]. The phys-
ical up-and down movement of the gut during running
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symptoms [41]. Interactions between prolonged exercise,
challenging environmental conditions (temperature, alti-
tude, humidity, etc.), and nutrient and fluid intake may also
increase risk of gut problems [130]. Disruption in the GI
system can impair the delivery of nutrients, and cause GI
symptoms and decreased performance. The GI tract and
particularly the gut are quite adaptable and can be targeted
to improve the delivery of nutrients during exercise while
at the same time alleviating some (or all) of the symptoms
[131]. A major limitation of studies in this field is that the
prevalence of GI illnesses overall is quite low, which makes
it difficult to study without a large number of subjects. Pro-
biotic supplementation in combination with other dietary
strategies (e.g. consuming well-tolerated foods and drinks,
avoiding spicy foods) could assist athletes with a history of
GI problems. Moreover, probiotic supplementation poten-
tially could improve GI health which has several indirect
athletic benefits. Of the ten studies that assessed GI benefit
in athletes and physically active individuals, the majority re-
ported no effect. However, the methodology varied consid-
erably, including probiotic type (species/strain), dosing,
duration and study participants, making comparison diffi-
cult. Further, the overall result is not conclusive as four
studies reported positive results. This latter group included
significantly decreased concentrations of zonulin [63] and
endotoxin [77], as well as intestinal hyperpermeability [132]
and duration of GI-symptom episode. Research in this area
has only been conducted intermittently over the past 10
years, with the need for future studies apparent.
In the first reported study investigating the effects of
probiotics on GI health, Kekkonen et al. [55], reported no
effect of L. rhamnosus GG on GI-symptom episodes in
marathon runners after a three-month training period.
However, the duration of a GI symptom episode was 57%
shorter in the probiotic group than in the placebo group.
Eight weeks of supplementation with a multi-strain pro-
biotic yogurt in adolescent female endurance swimmers
did not affect GI symptoms [44]. In a study of elite union
rugby players, subjects given a multi-strain probiotic over
4 weeks did not experience a significant reduction in GI
episodes (including nausea, vomiting, diarrhea) compared
to the placebo [69].
Investigating markers of gut permeability, West et al.
[66] found no significant effect of multi-strain probiotic
supplementation on the lactulose/mannitol ratio in active
individuals after 3 weeks. Lamprecht et al. [63] explored
the effects of 14 weeks of multi-species probiotic supple-
mentation on zonulin from feces in trained men. Zonulin
concentrations decreased significantly from slightly above
normal into the physiological range in subjects that sup-
plemented with the probiotics. Zonulin is a protein of the
haptoglobin family released from liver and intestinal epi-
thelial cells and has been described as the mainphysiological modulator of intercellular tight junctions
[133]. Increased zonulin concentrations are related to
changes in tight junction competency and increased GI
permeability [133]. The “leak” in the paracellular absorp-
tion route enables antigens to pass from the intestinal en-
vironment, challenging the immune system to produce an
immune response and subsequent inflammation and oxi-
dative stress [134–136]. Lamprecht et al. [63] suggested
that the supplemented probiotics may activate the TLR2
signaling pathway resulting in improved intestinal barrier
function, thus reducing an athlete’s susceptibility to endo-
toxemia and associated cytokine production [137].
Shing et al. [46] tested the effects of 4 weeks of multi-
strain probiotics supplementation on GI permeability when
exercising in the heat in a small group of male runners. To
assess GI permeability, subjects ingested lactulose and
rhamnose before exercise and post-exercise urine was col-
lected to measure the ratio. Further, urinary claudin-3, a
surrogate marker of gut barrier disruption, and serum lipo-
polysaccharide (LPS) were measured. There was no signifi-
cant effect on lactulose:rhamnose ratio, urinary claudin-3
or serum LPS and it is possible that 4 weeks may not have
been sufficient to detect changes. In short-term, high dose
single-strain probiotic supplementation (L. casei), male run-
ners under heat stress did not exhibit any marked changes
in resting circulatory endotoxin concentration or plasma
cytokine profile compared with placebo [76]. Conversely,
Roberts et al. [77] reported 12weeks of supplementation
with a multi-strain probiotic/prebiotic significantly reduced
endotoxin levels in novice distance triathletes. However, no
difference was identified in the assessment of intestinal per-
meability from urinary lactulose:mannitol ratio. This effect
was reported both pre-race and 6 days post-race. Addition-
ally, seven highly-trained endurance athletes who received
4 weeks of L. salivarius (UCC118) attenuated exercise-
induced intestinal hyperpermeability [132]. Most recently,
12 weeks of probiotic supplementation (B. subtilis DE111)
had no effect on gut permeability as measured by zonulin
in Division I baseball players [83].
Key Points 4 – Probiotic Supplementation and Gastrointestinal
Health.
• GI problems often occur in endurance athletes and can impair the
delivery of nutrients, cause GI symptoms and decrease performance.
• A small number of studies assessing GI benefit in athletes and
physically active individuals have yielded mixed results with
considerable variation in methodology, making comparison difficult.
• Positive results reported included decreases in concentrations of
zonulin and endotoxin, intestinal hyperpermeability and duration of
GI-symptom episodes.Mechanism of action
Given that different strains and product formulations exist,
explaining the mechanism of action becomes a rather
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research is that a mechanism of action involving the gut
microbiota is not confirmed, or even examined, in the
majority of cases and there certainly are mechanisms
outside of the GI tract systemically and in other
microbiota niches. Clinical studies track probiotic “inputs”
(whether a single strain or multiple strains) and health
“outputs”, often without knowing what happens in
between. This shortcoming further emphasizes the need
to not use the general term probiotics, when describing
mechanisms of action, but try to specify the strains [138].
This does not mean the mechanisms are the same for
each strain, nor that precise mechanisms have been
proven. For example, bacterial strains such as L. reuteri
SD2112 (ATCC 55730) and L. reuteri RC-14 are different
genetically and functionally, with the former producing
reuterin believed to be important for inhibition of patho-
gens in the gut [139] and the latter producing biosurfac-
tants that inhibit attachment of uropathogens [140].
Finally, several food products and dietary supplements
may contain multiple species and strains in the same
product. To fully explain the in-depth mechanisms of ac-
tion is both out of the scope of this Position Statement
and poorly understood in general. However, interested
readers are directed to other resources [138, 141]. The
question whether multi-strain or multi-species probiotics
are better than single strain or single species probiotics
depends on the outcome measure, dosage, and study
population. Potential additive or even synergistic benefits
would need to be validated in a control clinical study, and
currently those data do not exist. Mechanisms of action in
relation to the effects of probiotic supplementation in ath-
letes has been less described [40]. Here we discuss support
of the gut epithelial barrier, increased adhesion to intes-
tinal mucosa, the effects of postbiotics, modulation of the
immune system, and improved nutrient absorption.
Support of the gut epithelial barrier
The intestinal barrier is a major defense mechanism used to
maintain epithelial integrity and protect the host from the
environment. Defenses of the intestinal barrier consist of
the mucous layer, antimicrobial peptides, secretory IgA and
the epithelial junction adhesion complex [142]. Once this
barrier function is disrupted, bacterial and food antigens can
reach the submucosa and induce inflammatory responses
[143, 144]. Consumption of non-pathogenic bacteria can
contribute to intestinal barrier function, and probiotic bac-
teria have been extensively studied for their involvement in
the maintenance of this barrier. However, the mechanisms
by which probiotics enhance intestinal barrier function are
not fully understood. Anderson et al. [145] indicated that
enhancing the expression of genes involved in tight junction
signaling is a possible mechanism to reinforce intestinal bar-
rier integrity. Probiotics may promote mucous secretion asone mechanism to improve barrier function and the exclu-
sion of pathogens. Several Lactobacillus species have been
noted to increase mucin expression in human intestinal cell
lines and, in the case of a damaged mucosa, may thus help
restoration of the mucus layer. However, this protective ef-
fect is dependent on Lactobacillus adhesion to the cell
monolayer, which likely does not occur in vivo [146, 147].
Therefore, mucous production may be increased by probio-
tics in vivo, but further studies are needed to make a con-
clusive statement.
Strenuous and prolonged exercise place stresses on the
GI tract that increase the likelihood of discomfort,
abdominal cramping, acid reflux (heartburn), nausea,
vomiting, diarrhea, and permeability of the gut that may
allow endotoxemia to occur [41]. Splanchnic hypoperfusion
leading to ischemia in the gut is accepted as a principal
cause, with additional contributions from nutritional,
mechanical (e.g., jarring), and genetic influences that make
some individuals more susceptible than others [41].
Probiotic support to increase resilience of the GI tract
against ischemia is of interest to athletes, particularly for
those involved in prolonged endurance events that have the
greatest occurrence of GI problems that can impair or stop
performance. Mechanistically, prolonged or strenuous
exercise may increase key phosphorylation enzymes [148],
disrupting tight junction proteins claudin (influenced by
protein kinase A) and occludin (influenced by both protein
kinase C and tyrosine kinase). Acute changes in tight
junction permeability and paracellular transport may lead
to a greater prevalence of systemic LPS. LPS from Gram-
negative intestinal bacteria may provoke immune responses
and endotoxin-associated symptoms characteristic of GI
complaints often experienced in runners [148]. Despite this,
research is relatively sparse on whether prolonged training
or ultra-endurance events actually result in elevated LPS,
particularly in more “recreationally active” athletes; or
whether targeted nutrition strategies offer beneficial sup-
port. LPS translocation across the GI tract can provoke sys-
temic immune reactions with varied consequences [149].
Specifically, LPS attachment to LPS-binding protein and its
transference to an MD 2/TLR4/CD14 complex activates
NF-κB and various inflammatory modulators (TNF-α, IL-
1β, IL-6 and CRP). This sequence is considered a protective
mechanism to minimize bacterial entry across the GI tract.
Under normal physiological conditions, endotoxins from
gram negative bacteria are usually contained locally, with
only relatively small quantities entering the systemic circu-
lation. However, when GI defenses are either disrupted (i.e.,
luminal damage from exercise) or LPS “sensing” is “over-
loaded”, a heightened inflammatory response may result
which could, in part, relate to GI symptoms associated with
exercise [150]. This effect could have implications for daily
recovery strategies throughout prolonged training periods,
and in the days following ultra-endurance events.
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intervention maintains tight junction stability. Further, stud-
ies have demonstrated that regular use of probiotics can im-
prove epithelial resistance by establishing competitive
“biofilm” formation. Indeed, as LPS types vary across Gram-
negative bacteria species, some LPS are poorly sensed by
TLR4 and may have more direct impact on NF-κB activation
[151]. Therefore, prevention of LPS translocation through
maintained epithelial integrity and/or increased preponder-
ance of Gram-positive genera may offer potential therapeutic
benefit [152]. Specifically, the provision of bacteria belonging
to the Lactobacillus genus may work by activating TLR2 and
hence produce more favorable innate immune responses
[153, 154]. Supplementation with a multi-strain probiotic for
14weeks decreased fecal zonulin levels, supporting improved
tight junction stability through improved intestinal barrier in-
tegrity [63]. A mechanistic explanation for an improved in-
testinal barrier function after probiotic treatment is provided
by Karczewski et al. [155], who postulate that certain lactic
bacteria might activate the TLR2 signaling pathway. TLR2 is
localized in the membranes of intestinal wall cells and from
there communicates with microbial products from Gram-
positive bacteria [115]. Furthermore, activation of the TLR2
signaling pathway can enhance epithelial resistance in vitro
[156]. Therefore, supplemented probiotics may suppress bac-
teria that activate the zonulin system (e.g. Gram-negative
bacteria), settle in the deep intestine, and activate the TLR2
signaling pathway.
Adhesion to intestinal mucosa
“Competitive exclusion” is a term used to describe the
vigorous competition of one species of bacteria for receptor
sites in the intestinal tract over another species. The
mechanisms used by one species of bacteria to exclude or
reduce the growth of another species include: creation of a
hostile microecology, elimination of available bacterial
receptor sites, production and secretion of antimicrobial
substances and selective metabolites, and competitive
depletion of essential nutrients [141]. Adhesion of probiotics
to the intestinal mucosa has been shown to favorably
modulate the immune system [157, 158] and pathogen
antagonism [159]. In addition, probiotics are able to initiate
qualitative alterations in intestinal mucins that prevent
pathogen binding [160] while some probiotic strains can also
induce the release of small peptides or proteins (i.e.,
defensins) from epithelial cells [161]. These small peptides/
proteins are active against bacteria, fungi and viruses [162]
and may stabilize the gut barrier function [163]. Specific
adhesiveness properties related to the interaction between
surface proteins and mucins may inhibit the colonization of
pathogenic bacteria and are a result of antagonistic activity
by some strains of probiotics against adhesion of GI
pathogens [164]. For example, lactobacilli and bifidobacteria
can inhibit a broad range of pathogens, including E. coli,Salmonella, Helicobacter pylori, Listeria monocytogenes, and
Rotavirus [165–171]. To gain a competitive advantage,
bacteria can also modify their environment to make it less
suitable for their competitors, such as producing
antimicrobial substances (i.e., lactic and acetic acid) [172].
Some lactobacilli and bifidobacteria share carbohydrate-
binding specificities with certain enteropathogens [173, 174],
which makes it possible for the strains to compete with spe-
cific pathogens for the receptor sites on host cells [175]. In
general, probiotic strains are able to inhibit the attachment
of pathogenic bacteria by means of steric hindrance at en-
terocyte pathogen receptors [176].
Postbiotics
Postbiotics comprise metabolites and/or cell-wall compo-
nents released by probiotics and offer physiological benefits
to the host by providing additional bioactivity [4]. The poten-
tial benefits of these metabolites and/or cell wall components
should not only be considered to be associated with probio-
tics but more generally to metabolites produced by bacteria
during fermentation, including bile acid fermentation. Sev-
eral compounds have been collected from several bacteria
strains including SCFAs, enzymes, peptides, teichoic acids,
peptidoglycan-derived muropeptides, endo- and exo-
polysaccharides, cell surface proteins, vitamins, plasmalogens,
and organic acids [177–179]. Despite the fact that the mech-
anisms implicated in the beneficial health effects of postbio-
tics are not fully elucidated, they possess different functional
properties including, but not limited to, antimicrobial, anti-
oxidant, and immune modulation [4]. These properties can
positively affect the microbiota homeostasis and/or the host
metabolic and signaling pathways, physiological, immuno-
logical, neuro-hormone biological, regulatory and metabolic
reactions [180, 181].
In the majority of cases, postbiotics are derived from
Lactobacillus and Bifidobacterium species; however,
Streptococcus and Faecalibacterium species have also been
reported as a source of postbiotics [177, 179]. SCFAs
produced by the gut microbiota act as signaling molecules
improving regulation of lipid metabolism, glucose
homeostasis, and insulin sensitivity through the activation of
receptors such as G protein-coupled receptors (GPRs) to
regulate of energy balance while maintaining metabolic hom-
oeostasis [182, 183]. Specific SCFAs (e.g. butyrate, acetate and
propionate) also contribute to plasma cholesterol homeostasis
in rodents and humans [184]. Some studies [185–187] deter-
mined that cell-free extracts from lactic acid bacteria exhibit
higher antioxidant capacity than whole cell cultures, suggest-
ing that the antioxidant capacity could be attributed to both
enzymatic and non-enzymatic intracellular antioxidants.
Through postbiotic action, it seems plausible that
probiotics can increase exercise performance as seen
through a delay in fatigue in athletes by virtue of their
production of SCFAs. In addition, species within the
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to butyrate and later to acetyl-CoA, which is used in the
Krebs Cycle to generate adenosine triphosphate (ATP).
However, these processes occur mostly in the gut so whether
or not this would impact skeletal muscle performance re-
mains to be determined [188]. Another mechanism is by
antioxidant action, which can attenuate muscle injury in-
duced by reactive oxygen species, among others [92]. Anti-
oxidant effects found in probiotics are linked to the synthesis
of antioxidant substances such as vitamins B1, B5 and B6
[141]. Moreover, probiotic supplementation reduces the risk
of developing hyperglycemia, a condition known to be linked
to oxidative stress [189, 190]. Finally, the improvement in in-
testinal homeostasis, including the absorption process, may
favor the absorption of antioxidants, increasing the availabil-
ity of these substances [58].
One of the proposed mechanisms involved in the health
benefits afforded by probiotics includes the formation of
low molecular weight compounds (< 1000Da), such as
organic acids, and the production of antibacterial
substances termed bacteriocins (> 1000Da). Organic acids,
in particular acetic acid and lactic acid, have a strong
inhibitory effect against Gram-negative bacteria, and are
considered the main antimicrobial compounds responsible
for the inhibitory activity of probiotics against pathogens
[191–193]. The undissociated form of the organic acid en-
ters the bacterial cell and dissociates inside its cytoplasm.
The eventual lowering of the intracellular pH or the intra-
cellular accumulation of the ionized form of the organic
acid can lead to the death of the pathogen [194].
Intestinal bacteria also produce a diverse array of
health-promoting fatty acids. Certain strains of intestinal
bifidobacteria and lactobacilli can produce conjugated
linoleic acid (CLA), a potent anti-carcinogenic agent [195,
196]. An anti-obesity effect of CLA-producing L. plan-
tarum has been observed in diet-induced obesity in mice
[197]. Recently, the ability to modulate the fatty acid com-
position of the liver and adipose tissue of the host upon
oral administration of CLA-producing bifidobacteria and
lactobacilli has been demonstrated in a murine model
[196]. Finally, certain probiotic bacteria are able to pro-
duce so-called de-conjugated bile acids, which are deriva-
tives of bile salts. De-conjugated bile acids show a
stronger antimicrobial activity compared to that of the bile
salts synthesized by the host organism [141].
Modulation of the immune system
Numerous studies have shown that prolonged intense
physical exercise is associated with a transient depression of
immune function in athletes. While moderate exercise
beneficially influences the immune system [198], a heavy
schedule of training and competition can impair immunity
and increase the risk of URTIs due to altered immune
function [116, 199, 200]. Both innate immunity and acquiredimmunity are decreased following prolonged exercise [199–
201]. It is well known that probiotic bacteria can exert an
immunomodulatory effect; however, research from non-
athletic populations may not be translatable to athletes. Fur-
ther, the manipulation and control of the immune system by
probiotics is difficult to evaluate and make general conclu-
sions. However, several studies investigating the effects of
probiotics in athletes have reported improvement in low-
grade inflammation [42, 63], as well as increased resistance
to URTIs [57, 60, 69, 78] and reduced duration of URTI [79].
Modulation of the immune system to increase defenses
against URTIs currently is the most extensively researched
area. The GI tract is a major gateway for pathogen entry,
and as such, is heavily protected by the immune system. The
immune system can be divided between the innate and
adaptive systems. The adaptive (acquired) immune response
depends on B and T lymphocytes, which are specific for
particular antigens. In contrast, the innate immune system
responds to common structures called pathogen-associated
molecular patterns (PAMPs) shared by the vast majority of
pathogens [202]. The primary response to pathogens is trig-
gered by pattern recognition receptors (PRRs), which bind
PAMPs. The best-studied PPRs are TLRs. In addition, extra-
cellular C-type lectin receptors (CLRs) and intracellular
nucleotide-binding oligomerization domain-containing pro-
tein NOD-like receptors are known to transmit signals upon
interaction with bacteria [203]. It is well established that pro-
biotics can suppress intestinal inflammation via the downreg-
ulation of TLR expression, secretion of metabolites that may
inhibit TNF-α from entering blood mononuclear cells, and
inhibition of NF-ĸB signaling in enterocytes [202].
Probiotics can enhance innate immunity (first-line-of-
defense) by upregulating immunoglobulins, antimicrobial
proteins, phagocytic activity, and natural killer cell activity, and
enhance acquired immunity by improving antigen
presentation and function of T and B lymphocytes to
neutralize pathogens and virally-infected cells [10, 204]. These
effects are of particular importance to athletes because exer-
cise may increase susceptibility to URTIs by decreasing saliv-
ary IgA, decreasing cell-mediated immunity by decreasing
type 1T lymphocytes to make recurrent infections more
likely, and increasing glucocorticoid suppression of monocyte/
macrophage antigen presentation and T lymphocyte functions
[205, 206]. The majority of placebo-controlled clinical trials
assessing the efficacy of probiotics for reducing incidence, dur-
ation, and severity of URTI in athletes report beneficial out-
comes. However, many different probiotics have been used
and the differences in trial protocols and outcome measures
complicate the drawing of more specific conclusions.
Improved nutrient absorption
Supplementation with some probiotic strains has been
suggested to improve dietary protein absorption and
utilization [207]. While not fully elucidated, several studies
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action is lacking. As noted, probiotics can potentially improve
intestinal barrier function by modulating tight junction
permeability which may improve nutrient absorption.
Improving the digestibility of protein can speed recovery
of strength after muscle-damaging exercise [209], and pro-
mote glycogen replenishment after exercise. B. coagulans
produce digestive enzymes [97] active under gut condi-
tions (alkaline proteases). These proteases can digest pro-
teins more efficiently than the endogenous human
proteases alone [96]. B. coagulans GBI-30, 6086 enhances
the health of the cells of the gut lining improving nutrient
absorption including minerals, peptides, and amino acids
by decreasing inflammation and encouraging optimum
development of the absorptive area of the villi [98].
In a computer-controlled in vitro model of the small in-
testine, B. coagulans GBI-30, 6086 enhanced amino acid
absorption while improving colon health [208]. In
recreationally-trained males, Jäger et al. [43] found the co-
administration of B. coagulans GBI-30, 6086 and 20 g of
protein improved recovery 24 and 72 h, and muscle sore-
ness 72 h post-exercise. Furthermore, Toohey et al. [103],
noted B. subtilis DE111 supplementation with a post-
workout recovery drink containing 20 g of protein reduced
body fat percentage after 10 weeks of resistance training
compared with the same post-workout recovery drink and
a placebo in female athletes. Toohey et al. [103] speculated
improved amino acid uptake in the probiotic group may
have resulted from more efficient protein digestion, simu-
lating the effects of a higher daily protein intake.
Key Points 5 – Mechanisms of Action
• There are dozens of bacterial strains that can be considered as
probiotics, particularly those that produce lactic acid. However, each
strain is unique with respect to how it responds to and affects the host.
• The mechanisms underlying the beneficial effects of probiotics in
athletes are largely unknown but are likely to be multifactorial.
• Consumption of some probiotic strains may improve intestinal barrier
function by modulating tight junction permeability. However, the
mechanisms by which probiotics enhance intestinal barrier function are not
sufficiently studied.
• Adhesion of probiotics to the intestinal mucosa may be a
mechanism for modulation of the immune system. Probiotics also
cause alterations in intestinal mucins that prevent pathogen binding.
• Probiotics may support microbiota and postbiotic production which
possess different functional properties including, but not limited to,
antimicrobial, antioxidant, and immunomodulatory.
• Probiotics may enhance innate immunity by upregulating
immunoglobulins, antimicrobial proteins, phagocytic activity, and
natural killer cell activity, and also enhance acquired immunity by
improving antigen presentation and function of T and B lymphocytes
to neutralize pathogens and virally-infected cells.
• Probiotics can potentially modulate intestinal permeability and health
of the cells of the gut lining improving nutrient absorption including
minerals, peptides, and amino acids by decreasing inflammation and
encouraging optimum development of the absorptive area of the villi.Safety and health
The concept of probiotics is not new. Around 1900
Nobel laureate, Elie Metchnikoff, discovered that the
consumption of live bacteria (L. bulgaricus) in yogurt or
fermented milk improved some biological features of
the GI tract [210]. Bacteria with claimed probiotic
properties are now widely available in the form of foods
such as dairy products and juices, and also as capsules,
drops, and powders. Probiotics have been used safely in
foods and dairy products for over a hundred years.
Some of the most common commercially available
strains belong to the Lactobacillus and Bifidobacterium
genera. In this respect, well-studied probiotic species in-
clude Bifidobacterium (ssp. adolescentis, animalis, bifi-
dum, breve, and longum) and Lactobacillus (ssp.
acidophilus, casei, fermentum, gasseri, johnsonii, reuteri,
paracasei, plantarum, rhamnosus, and salivarius) [211].
An international consensus statement in 2014 indicated
that these are likely to provide general health benefits
such as normalization of disturbed gut microbiota, regu-
lation of intestinal transit, competitive exclusion of
pathogens, and production of SCFAs [1].
Beyond athletes and physically active individuals, there
is a large body of preclinical and clinical research on the
GI benefits of probiotics in healthy individuals and in a
wide range of health conditions. These applications
include treatment and prevention of acute diarrhea,
prevention of antibiotic-associated diarrhea, treatment of
hepatic encephalopathy, symptomatic relief in irritable
bowel syndrome, and prevention of necrotizing entero-
colitis in preterm infants [212]. Overall, probiotics have
an excellent safety profile with a large majority of clinical
trials involving probiotics not giving rise to major safety
concerns [213]. Of the adverse events (AEs) commonly
reported, Marteau [214] outlined four classes of possible
side effects of probiotic use: systemic infections, detri-
mental metabolic effects, cytokine-mediated immuno-
logic adverse events in susceptible individuals, and
transfer of antibiotic resistance genes. Of these, particu-
lar concern relates to probiotics potential to create (not
improve or treat) systemic infections [49, 64, 215]. Fur-
ther, probiotics have been studied in vulnerable groups,
including infants, patients with severe acute pancreatitis,
inflammatory bowel diseases, liver diseases, HIV, and
other conditions [213, 216–218] with even greater cause
for concern with the small number of products that con-
tain high concentrations of up to 450–900 billion live
bacteria per dose [211]. Many of the studies reporting
AEs (rarely serious AEs) either do not utilize the appro-
priate biological sampling and identification techniques
or AEs are poorly reported.
Commercially available probiotic products can be divided
into single-strain (defined as containing one strain of a
well-defined microbial species) and multi-strain (containing
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term multispecies is also used for products that contain
strains from more than one genus [211], for example a
product with a L. acidophilus strain, a L. reuteri strain, and
a B. longum strain. Treatment with probiotics may involve
the consumption of large quantities of bacteria, so safety is
a primary concern. There are two aspects to safety: estab-
lishing the adverse effect profile of specific single-strain and
multi-strain supplements (i.e., the safety of the strain(s) per
se), and ensuring that marketed supplements meet strin-
gent quality standards to ensure the correct strains are
present and the product is free of contamination [217].
Safety assessments should take into account the nature
of the specific probiotic microbe, method of
administration, level of exposure, health status of the
recipients, and the physiological functions the microbes
are intended to perform [213]. However, most probiotics
in commercial use are derived from fermented foods
with a long history of safe consumption, or from
microbes that may colonize healthy humans [212]. All
common probiotic species are considered safe for the
general population by the European Food Safety
Authority (EFSA), although this definition does not
provide guidance on the increasing use of probiotics in
people with medical conditions. Moreover the benefits
of probiotics are not validated by EFSA, jeopardizing the
use of the term probiotic without an approved claim
with some exceptions such as in Italy, Czech Republic,
and Bulgaria [211]. Going beyond history of safe use,
since 2007 the EFSA lists species presumed safe for
human consumption under the “Qualified Presumption
of Safety” (QPS) concept. The approach is based on
experience that for selected organisms there are no
reasonable safety concerns for human health. The list
regularly monitors the body of knowledge through
extensive scientific literature review, applied to a wide
array of micro-organisms added in the food-chain. The
QPS list concerns consumption by the general healthy
population and does not take into consideration poten-
tial risks for vulnerable populations and this is clearly
mentioned. The U.S. Food and Drug Administration
(FDA) classifies probiotics individually but has classified
many as Generally Recognized As Safe (GRAS), safe for
the use in foods and infant products [219].
A systematic literature review of probiotic safety
published in 2014 reported that “the overwhelming
existing evidence suggests that probiotics are safe” for
the general population, and that critically ill patients,
postoperative and hospitalized patients and
immunocompromised patients were the most at-risk
groups wherein AEs occurred [220]. The general con-
sensus is that probiotic ingestion is safe [221, 222], with
large doses well tolerated and failing to exhibit any tox-
icity [223]. Indeed, low CFU dosage and interventionperiods between 2 weeks to 6 months are generally used
within clinical research models [224, 225]. In this pos-
ition stand, which reviews studies focused on probiotic
supplementation in athletes and physically active indi-
viduals, 11 studies measured AEs and general supple-
mentation tolerance, while 30 studies did not. Of the 11
studies, a general consensus was made to conclude that
probiotic supplementation was generally well tolerated
with a very low level of adverse health effects. There was
one instance in which mild GI symptoms (5 episodes)
were reported, including flatulence and stomach rumbles
during supplementation with a multi-strain probiotic in
22 active individuals [66]. AEs are often not well re-
corded in nutritional studies in general and probiotics
are no exception to this. Overall, from the current body
of research probiotic supplementation for healthy ath-
letes and physically active individuals appears safe. Cau-
tion is warranted for those with serious health
conditions, such as severe acute pancreatitis, inflamma-
tory bowel diseases, liver diseases, and HIV. In these in-
stances, it is advised that the patient consult with their
health care practitioner before supplementing. Another
consideration is supplementing evidence-based dosages
and keeping the probiotic properly stored. Unlike, other
familiar sports supplements, probiotics are live organ-
isms and may require specific storage requirements in-
cluding refrigeration.
Key Points 6 – Safety and Health.
• Probiotics have been used safely in foods and dairy products for
over a hundred years.
• Well-studied probiotic species include Bifidobacterium (ssp. adolescen-
tis, animalis, bifidum, breve, and longum) and Lactobacillus (ssp. acid-
ophilus, casei, fermentum, gasseri, johnsonii, reuteri, paracasei,
plantarum, rhamnosus, and salivarius).
• Safety assessments should take into account the nature of the
probiotic microbe, method of administration, level of exposure, health
status of the recipients, and the underlying physiological functions
the microbes are intended to perform.
• Four classes of possible side effects are commonly reported from
probiotic use in vulnerable patient groups: systemic infections,
detrimental metabolic effects, cytokine-mediated immunologic ad-
verse events in susceptible individuals, and transfer of antibiotic resist-
ance genes.
• The current body of research of probiotic supplementation for
healthy athletes and physically active individuals suggests that they
are safe for use.
• Caution is warranted for those with serious health conditions. In
these instances, patients should consult with their health care
practitioner before supplementing.
• Consumers are advised to supplement with probiotics strains and
products within evidence-based dosages.Regulation
Currently there is no clear set of recommendation or
guidelines on probiotic use for athletes. The current body
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strains, duration of use, and dosages with several different
intended purposes (Table 4). The effects of probiotics are
strain specific, and therefore, strain identity is important to
link to a specific health effect as well as to enable accurate
surveillance and epidemiological studies. Unfortunately,
government regulatory organizations are highly varied
across national borders and jurisdictions in regulation of
probiotics, making uniform recommendations difficult.
In 2001, the FAO/WHO held the Expert Consultation on
Evaluation of Health and Nutritional Properties of
Probiotics, to develop standardized guidelines for evaluating
probiotics in food that could lead to the substantiation of
health claims [226]. The proposed guidelines recommend:
1) identifying of the genus and species of the probiotic
strain by using a combination of phenotypic and genotypic
tests as clinical evidence suggesting that the health benefits
of probiotics may be strain specific, 2) in vitro testing to
delineate the mechanism of the probiotic effect, and 3)
substantiating the clinical health benefit of probiotic agents
with human trials. Additionally, safety assessment of the
probiotic strain should at a minimum determine: 1)
patterns of antimicrobial drug resistance, 2) metabolic
activities, 3) side effects noted in humans during clinical
trials and after marketing, 4) toxin production and
hemolytic potential if the probiotic strain is known to
possess those properties, and 5) lack of infectivity in animal
studies [226].
The regulation of probiotics differs between countries as
there is no universally agreed framework. For the most
part, probiotics are categorized as food and dietary
supplements because most are delivered by mouth as a
food or supplement. For example, Health Canada has
provided a Natural Health Product monograph that
includes dosage form(s), use(s) or purpose(s) recommended
as well as minimum quantities for L. johnsonii (La1/Lj1/
NCC 533, an adjunct to physician-supervised antibiotic
therapy in patients with H. pylori infections, 1.25 × 108
CFU) (all strains, 1 × 107 CFU), L. rhamnosus (GG, Man-
agement of acute infectious diarrhea, 6 × 109 CFU, manage-
ment/risk reduction of antibiotic-associated diarrhea, 1 ×
1010 CFU) (all strains, 1 × 107 CFU), and S. boulardii / S.Table 4 Dosage range in studies investigating the effect of
specific probiotic genera in athletes and physically active
individuals
Type Dosage range
Lactobacillus (n = 35) 1 × 109 – 10 × 1010 CFU
Bifidobacterium (n = 18) 7 × 107–9.5 × 109 CFU
Streptococcus (n = 8) 5 × 109–4.5 × 1010 CFU
Bacillus (n = 5) 5 × 108 – 5 × 109 CFU
Multi- species/strain (n = 17) 2 × 109–4.5 × 1010 CFUcerevisiae (all strains, Risk reduction of antibiotic-associated
diarrhea, 1 × 1010 CFU) (all strains, 1 × 107 CFU). The pro-
biotic product monograph contains both bacteria and fungi
which have been pre-approved for the use or purpose
which allows claims; “source of probiotics”, “helps support
intestinal/gastrointestinal health”, “could promote a favor-
able gut flora” with 1 × 107 CFU daily. The minimum daily
dose is the sum of CFU per day provided by all live micro-
organisms that are present in the product, and not the
minimum amount of CFU per day for each of the microor-
ganisms. Further, a duration of use statement is not re-
quired, nor is there any guidance provided. Cautions
include; “If you have fever, vomiting, bloody diarrhea, or se-
vere abdominal pain, consult a health care practitioner
prior to use” and “If symptoms of digestive disorders (e.g.,
diarrhea) occur, worsen and / or persist beyond 3 days, dis-
continue use and consult a health care practitioner.” [227].
In Canada, probiotics have two modes of sale on the mar-
ket, Natural and Non-Prescription Health Products Direct-
orate (NNHPD) and Food Directorate [3, 228]. Health
Canada uses a pre-market approval process for non-food
like applications such as capsules, tablets, softgels and pow-
ders which requires companies to acquire a Natural Prod-
uct Number (NPN) prior to bringing to market [3]. Table 5
below details the current licensed products and claims spe-
cific to sport performance using probiotic strain(s) in or
outside the pre-approved monograph. This list is open ac-
cess through the Health Canada LCNHPD (Licensed Nat-
ural Health Products Database) which allows consumers
and retailers the ability to review claims on packaging to
approved claims by the NNHPD [229].
Japan is viewed by many to be a global market leader
given that probiotics are available as both foods and
drugs [230], and was the first global jurisdiction to
implement a regulatory system for functional foods and
nutraceuticals in 1991. Under Japanese regulations,
probiotic products are in a distinct category of foods
known as Foods for Specific Health Uses (FOSHU). For
probiotic food products, efficacy claims are prohibited
on the labeling. If claims are to be made about efficacy,
one must obtain special permission from the Ministry of
Health and Welfare (MHLW) for the product to be
considered FOSHU, for which substantiation of efficacy
and safety is a mandatory requirement [231]. In Brazil,
probiotics are considered as functional foods, and
considered to be different from food. But legislation asks
for safety and efficacy demonstration of food products
and hence all these products must be registered and
approved by a health authority called National Health
Surveillance Agency Brazil (ANVISA) [230].
In the European Union, probiotics and food supplements
are regulated under the Food Products Directive and
Regulation (regulation 178/2002/EC; directive 2000/13/
EU). All health claims for probiotics have to be authorized
Table 5 Approved Canadian Probiotics Claims for Sports Performance
NPN Probiotic Species Used (Strains
if available) and Potency
Sport Specific Claims Supported by Research outside of monograph
80,080,
307
B. breve BR03 5 Billion CFU
S. salivarius ssp. thermophilus
FP4 5 Billion CFU
Helps maintain gastrointestinal health which may assist in normal recovery of performance
following exercise.
80,077,
863
B. coagulans GBI-30, 6086
1 Billion CFU
B. coagulans GBI-30, 6086 could be used to improve symptoms of delayed onset muscle
soreness (DOMS) after exercise.
B. coagulans GBI-30, 6086 helps maintain gastrointestinal health which may assist in a normal
recovery of performance following exercise.
80,040,
732
L. helveticus 400 million CFU
B. longum subsp. longum 600
million CFU
Helps maintain the health of the immune system following periods of physical stress.
80,064,
384
L. helveticus 10 Billion CFU Promotes gastrointestinal health in physically active adults
Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress
80,064,
386
L. helveticus 10 Billion CFU × 2 Promotes GI health in physically active adults
Helps support immune defenses against winter infections in healthy adults and in those
having weakened immunity due to intensive sports activities
Promotes GI health, immune health and general well-being in physically active adults
(including sporty individuals like athletes)
Reduces symptoms with upper respiratory tract infections
Helps reduce incidence of cold-like symptoms in adults with exercise-induced stress
With 20 Billion CFU per day, this product helps support the first line of body’s immune
defenses (IgA production), which may be associated with lowering URTI risk in physically
active adults (such as competitive athletes)
80,050,
736
B. animalis subsp. lactis 23
Billion CFU
B. animalis subsp. lactis 50
million CFU
B. animalis subsp. lactis 1 Billion CFU
B. bifidum 50 million CFU
B. longum subsp. infantis 100 million CFU
L. acidophilus 24.8 Billion CFU
L. acidophilus 1 Billion CFU
Reduces the risk of developing upper respiratory tract illness in physically active adults
Reduces the duration of URTI in physically active adults
80,064,
494
B. animalis subsp. lactis BI-04
10 Billion CFU
B. animalis subsp. lactis Bi-07
10 Billion CFU
L. acidophilus NCFM 10 Billion CFU
L. paracasei LPC-37 10 Billion CFU
Helps reduce the risk of developing URTI in physically active adults
80,068,
830
B. animalis subsp. lactis Bi-04 2
Billion CFU
Reduces the risk of developing URTI in physically active adults
Reduces the duration of URTI in physically active adults
80,080,
161
B. longum subsp. longum 320
million CFU
L. helveticus 2.68 billion CFU
L. helveticus 5 Biillion CFU
Promotes GI health, immune health and general well-being in physically active adults
(including sporty individuals like athletes)
Reduces symptoms associated with upper-respiratory tract illness (URTI). Helps shorten
the duration of URTI episodes
Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress
Helps support the first line of the body’s immune defenses (IgA production), which may
be associated with lowering URTI risk in physically active adults (such as competitive athletes)
Helps support immune defenses against winter infections in healthy adults and in those having
weakened immunity due to intensive sports activities
Helps to reduce gastrointestinal discomfort (e.g., abdominal pain, nausea, vomiting) in those
experiencing mild to moderate stress resulting from life events (e.g., academic exams)
Helps to moderate general feelings of anxiety
Promotes a healthy mood balance
Helps to reduce stress-related gastrointestinal complications such as abdominal pain
80,089,
514
B. bifidum 3 Billion CFU
L. helveticus 5 Billion CFU
Helps support immune defenses against winter infections in healthy adults and in those
having weakened immunity due to intensive sports activities
Helps to alleviate gastro-intestinal (GI) disturbances like flatulence, constipation, bloating
and abdominal cramps in healthy adults
Promotes GI health, immune health and general well-being in physically active adults
(including sporty individuals like athletes)
Reduces symptoms associated with upper-respiratory tract illness (URTI)
Helps shorten the duration of URTI episodes
Helps reduce the incidence of cold-like symptoms in adults with exercise-induced
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Table 5 Approved Canadian Probiotics Claims for Sports Performance (Continued)
NPN Probiotic Species Used (Strains
if available) and Potency
Sport Specific Claims Supported by Research outside of monograph
stress
Helps support the first line of the body’s immune defenses (IgA production), which
may be associated with lowering URTI risk in physically active adults (such as
competitive athletes)
Helps reduce the incidence of cold-like symptoms in stressed adults
80,091,
068
B. animalis subsp. lactis 2 Billion CFU
L. acidophilus 1 Billion CFU
L. acidophilus 3 Billion CFU
L. plantarum 14 Billion CFU
Reduces the risk of developing upper respiratory track illness in physically active adults
Reduces the duration of upper respiratory tract illness in physically active adults
80,091,
070
B. animalis subsp. lactis 2 Billion
L. acidophilus 1 Billion
L. acidophilus 3 Billion
L. plantarum 14 Billion
Reduces the risk of developing upper respiratory track illness in physically active adults
Reduces the duration of upper respiratory tract illness in physically active adults
80,087,
974
B. animalis subsp. lactis 2.81 Billion CFU
B. animalis subsp. lactis 1.47 Billion CFU
B. animalis subsp. lactis 810 million CFU
B. animalis subsp. lactis 530 million CFU
B. bifidum 28 million CFU
D-Glucose 13mg
D-Xylose 13 mg
L-Arabinose 7 mg
L. acidophilus 630 million CFU
L. casei 610 million CFU
L. paracasei 690 million CFU
L. plantarum 890 million CFU
L. salivarius 560 million CFU
Xylooligosaccharides 631 mg
Reduces the risk of developing upper respiratory track illness in physically active adults
Reduces the duration of upper respiratory tract illness in physically active adults
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have a Qualified Presumption of Safety [232], meaning that
they do not require safety assessments. The EFSA is also
responsible for assessing health claims made for probiotic
products. So far, EFSA has rejected all submitted health
claims for probiotics. While rigorous scrutiny of product
claims is apparent, there appears to be little regulation of
the manufacturing process and almost no post-marketing
regulatory follow-up [233].
In the United States, government regulation of
probiotics is complex. Depending on a probiotic product’s
intended use, the FDA might regulate it as a dietary
supplement, a food ingredient, or a drug. Many probiotics
are sold as dietary supplements, which do not require
FDA approval before they are marketed. Dietary
supplement labels are permitted to make claims about
how the product affects the structure or function of the
body without FDA approval, but they cannot make health
claims (claims that the product reduces the risk of a
disease) without the FDA’s approval [234]. Further,
dietary supplements are required to comply with Good
Manufacturing Practice guidelines, but these do not
extend to testing quality or efficacy [233]. From the
examples provided, it is apparent that the current
approach to regulation is inadequate and can lead to
problems of quality, safety, and claim validity in
commercial probiotic products used in a medical context,
including those used in vulnerable populations [233].In January 2017, the Council for Responsible Nutrition
(CRN) and the International Probiotics Association (IPA)
announced the development of scientifically-based best
practices manufacturing guidelines for the labeling, stor-
ing, and stability testing of dietary supplements and func-
tional foods containing probiotics [235]. These guidelines
were designed to facilitate transparency and consistency
in the probiotic sector. A key element of the guidelines is
labelling probiotic products in CFU, the scientifically ac-
cepted unit of measure for probiotics and used to report
probiotic quantity in many studies conducted to assess the
safety or benefits of probiotics. Consistent with scientific
literature, CFU are commonly used on probiotic product
labels in many jurisdictions around the world to help con-
sumers and healthcare professionals identify products pro-
viding probiotics in amounts shown to have benefit.
However, United States regulations require dietary ingre-
dients (with the exception of some vitamins) be labeled by
weight. Labeling probiotic quantity by weight is not mean-
ingful because this measure does not indicate the viability
of the microorganisms in the product throughout shelf
life. To the contrary, CFU are more representative of the
quantity of viable microorganisms and gives consumers
and healthcare professionals accurate information. The
FDA has recently agreed that in addition to weight, pro-
biotic amounts can also be labelled in CFU.
Upon examining the relevant literature investigating
the effects of probiotic supplementation on athletes and
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included Lactobacillus (n = 35), Bifidobacterium (n = 18),
Streptococcus (n = 8) and Bacillus (n = 5) (Table 3). In
addition, several studies used a combination of species
and strains (n = 17), ranging from two up to 14 different
species/strains. The dose of probiotic administered is an
important factor to be considered. In two reviews
related to dietary supplementation in athletes, dosing
regimens were reported in the range between 1 × 109 to
4 × 1010 CFU [10, 40]. In a 2018 consensus statement,
the International Olympic Committee noted moderate
support for probiotic use in athletes with a daily dose of
1 × 1010 live bacteria [5]. In our review, we report a wide
range of doses (Table 4), and in several studies the
dosage was not reported.
Similar to the type of probiotic used, the duration of
supplementation has also been variable in the studies
reviewed (Table 3). The shortest duration lasted 7 days
[75, 76] and the longest lasted 150 days [68]. The
duration and consistency of probiotic supplementation
are important factors. Coqueiro et al. [188] noted that
in clinical practice probiotic supplementation should be
implemented for at least 14 days prior to competition or
important events for the athlete. Therefore, studies that
supplement for a similar or shorter period should be
evaluated with caution. With the interruption of
probiotic intake, there is a reduction in the
microorganism administered in the colon, and with 8
days of supplementation discontinuation, the probiotic
is no longer detectable in the gut [236]. Finally, there is
some limited evidence that discrepancies exist between
males and females, even after supplementation of
probiotics with the same dose [61]. Future studies are
needed in this area, with the intention of establishing a
recommendation for each sex.
Key Points 7 Regulation
• No universally agreed upon framework exists for regulating
commercial products containing probiotics across countries globally.
• Probiotic products should be labelled in CFU, the scientifically
accepted unit of measure for probiotics and used to report probiotic
quantity in many studies conducted to assess the safety or benefits of
probiotics.
• Dosing regimens typically fall in range between 1 × 109 to 1 × 1011
CFU.
• The IOC noted moderate support for probiotic use when
administered for several weeks in athletes with a daily dose of 1 ×
1010 CFU.
• Genera of commonly used probiotics include Lactobacillus (n = 35),
Bifidobacterium (n = 18), Streptococcus (n = 8) and Bacillus (n = 5).
• Single-strain and multi- species/strain products are commonly used,
but combinations and individual dosing recommendations are not
currently understood
• Males and females may respond to probiotic supplementation
differently. Future research is needed in this area.Future directions
Overall, the effects of probiotics in athletes have
received less attention compared to animal studies and
human clinical conditions in the general population. A
PubMed search conducted in October 2019 yielded the
following listings for various combinations of key terms:
probiotic and athlete, n = 145; probiotic and rodent, n =
3407; probiotic and diabetes, n = 844; probiotic and
child, n = 2930; probiotic and elderly, n = 2257. Clearly,
the focus of the research community has been
investigating the beneficial effects of probiotics on gut
and immune health in various subgroups of the general
population. In animals, probiotics have been associated
with benefits including normalizing age-related drops in
testosterone levels [237], increasing neurotransmitter
synthesis [238], reducing stress-induced cortisol levels
[239], reducing inflammation [100] and improving mood
[240]. However, all these potential benefits lack current
substantiation in human intervention trials in an athletic
population. Here we discuss future research opportun-
ities to explore in relation to the microbiome and
athletes.
Body composition and muscle mass
It is well known that to increase levels of muscle mass,
resistance training must be included in exercise
regimens. Probiotic supplementation, both with and
without resistance training, can decrease levels of body
weight and fat mass in overweight and obese individuals,
as well as female athletes [103, 241, 242]. Increases in fat
free mass, however, have only been shown in animal
models. Chen and colleagues [92] supplemented male
Institute of Cancer Research (ICR) strain mice with L.
plantarum TWK10 for 6 weeks. Mice were divided into
three groups and daily doses of 0, 2.05 × 108, or 1.03 ×
109 CFU were given to each group, respectively. The
dosages chosen were modified from a comparable
human dose equivalent to mouse body size. Relative
muscle weight (%), as measured by combining the
gastrocnemius and soleus muscles, were significantly
increased in mice consuming the probiotic compared to
placebo. Additionally, the number of type I fibers were
increased significantly.
Mechanistically, it is plausible that Lactobacillus
strains decrease levels of inflammation, thereby
decreasing activation of intracellular proteins linked to
muscle atrophy, which may eventually link to an
observed increase in muscle mass. Chen et al. [92] also
determined that probiotic supplementation increased
forelimb grip strength and swim-to-exhaustion
performance in mice, which may or may not have been
related to improvement in muscle mass. Though
improvements in body composition have been shown
in humans, more studies examining decreased
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mass, in conjunction with reduction in fat mass, is
warranted.
Buffering capacity in exercising muscles
Physiological fatigue, such as extreme fatigue after
exercise, is accompanied by poor athletic performance
and loss of favorable working conditions for tissues
[243]. In response to higher intensity exercise, the
concentration of lactate and hydrogen ions increased
markedly resulting in an acidification in muscle and
subsequent fatigue [244, 245]. Approximately 75% of
the total amount of lactate produced is used for
oxidative production of energy in the exercising body
and can be utilized for the de novo synthesis of
glucose in the liver [246].
Probiotic supplementation may have potential to
remove and utilize blood lactate after exercise. For
instance, most Lactobacillus species produce lactic acid,
which could facilitate the production of butyrate by
lactate-utilizing bacteria that first produce acetyl-CoA
from lactate [247]. In the classical pathway, the enzymes
phosphotransbutyrylase and butyrate kinase convert
butyryl-CoA to butyrate and coenzyme A with concomi-
tant formation of ATP. Thus, probiotics and the gut
microbiota could play important roles in maintaining
normal physiology and energy production during exer-
cise. Several animal studies have been conducted with
promising results. In mice who consumed a probiotic
kefir daily over 4 weeks, swimming time-to-exhaustion
was significantly longer, forelimb grip strength was
higher and serum lactate, ammonia, blood urea nitrogen
(BUN), and creatine kinase levels were lower after the
swimming test [248]. In mice supplemented with L.
plantarum TWK10 over 6 weeks, supplementation dose-
dependently increased grip strength and endurance
swimming time and decreased levels of serum lactate,
ammonia, creatine kinase, and glucose after an acute ex-
ercise challenge [92]. Furthermore, the number of type I
fibers in gastrocnemius muscle significantly increased
with LP10 treatment. In a six-week human double-blind
placebo-controlled clinical study, young healthy amateur
runners supplemented with L. plantarum TWK10 and
underwent an exhaustive treadmill exercise measure-
ments and related biochemical indexes [85]. The
TWK10 group had significantly higher endurance per-
formance and glucose content in a maximal treadmill
running test compared to the placebo group (P < 0.05),
indicating that TWK10 supplementation may be benefi-
cial to energy harvest. Together, these studies suggest a
role in which certain probiotics may enhance energy
harvesting, and have health-promotion, performance-
improvement, and anti-fatigue effects. These are areas
that may warrant further research consideration.Considerations for future study designs
Several important methodological shortcomings in
research design should be addressed to improve scientific
evidence for the biological and clinical benefits of
probiotics. For example, discrepancies between men and
women, even after supplementation of probiotics with the
same dose, are evident [61]. In this sense, in studies with
both sexes, conflicting results may occur. In many
instances and products, the recommendation for probiotic
supplementation is no different for men and women,
necessitating studies investigating this topic, with the
intention of establishing a recommendation for each sex.
Other design concerns include the relatively small
number of subjects, which may compromise the
accuracy and interpretation of results. The period of
supplementation is another important factor as the
time of adaptation of the organism to the probiotic is
approximately 14 days. Thus, studies that supplement
for a similar or shorter period should be evaluated with
caution. Further, with the interruption of probiotic
intake, there is a reduction in the microorganism
administered in the colon, and with 8 days of
supplementation discontinuation, the probiotic is no
longer detectable in the gut [236]. In clinical practice, it
is common sense that probiotic supplementation
should be implemented for at least 14 days prior to
competition or important events for the athlete, given
that during this period the GI tract adapts to the
administered microorganism [188], and there may be
mild, transient GI symptoms, such as flatulence [10].
The long-term effects of probiotic administration in
athletes over several months or years on gut health, im-
mune function and rates of illness are unclear, as in
most studies the supplementation period was between
4 to 16 weeks.
Since many effects are dose-dependent, the amount of
probiotic administered is an important factor to be con-
sidered. The range of oral probiotic supplementation is,
approximately, 108–109 CFU per day, however, this value
varies in each country [249, 250] and notably, no specific
probiotic recommendation has been established for ath-
letes or physical activity practitioners. Most of the stud-
ies do not control for previous levels of physical activity,
so individuals within the same study may have very dif-
ferent levels of physical activity, making comparisons
unrealistic. Finally, very few studies have evaluated the
performance in strength exercises after supplementation
with probiotics and this is an important area of sports
and physical training to be studied.
Hormonal balance
Oral supplementation with selective bacteria holds promise
in positively affecting the endocrine system. In mice, the
microbiota can regulate testicular development and
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altered the microbiome [252]. Supplementation with a
selenium-enriched probiotic in conjunction with a high-fat
diet in male mice significantly alleviated the adverse effects
of hyperlipidemia by reducing testicular tissue injury, in-
creasing serum testosterone levels, and improving sperm
indexes [253]. Further, aging mice supplemented with the
probiotic bacterium L. reuteri had larger testicles and in-
creased serum testosterone levels compared to their age-
matched controls [237, 254].
In a human pilot study, supplementation with L.
acidophilus and B. longum (1 × 109 CFU) did not alter
plasma hormones, including testosterone, dihydrotesto
sterone, androstenedione, dehydroepiandrosterone sulfate,
and sex hormone-binding globulin, in 31 healthy males (18
to 37 years old) over a two-month period [255]. However,
another pilot study supplementing a probiotic and prebiotic
(L. paracasei B21060 5 × 109 cells + arabinogalactan 1243
mg + fructooligosaccharides 700mg + L-glutamine 500mg)
over 6 months in infertile male patients improved gonadal
pathway function including increased follicle stimulating
hormone, luteinizing hormone, and testosterone levels
compared to a control group [256].
Interestingly, Tremellen et al. [257] proposed that gut-
derived endotoxin can reduce gonadal function in obese
males. Obesity and a high fat/high calorie diet can alter
gut bacteria and intestinal wall permeability, leading to
the passage of LPS from within the gut lumen into the
circulation (metabolic endotoxemia), where it initiates
systemic inflammation [258]. Endotoxin can reduce tes-
tosterone production by the testes, both by direct inhib-
ition of Leydig cell steroidogenic pathways and indirectly
by reducing pituitary luteinizing hormone drive and
sperm production [259]. Tremellen and colleagues [257]
theorized the male reproductive axis has evolved the
capacity to lower testosterone production during times
of infection and resulting endotoxin exposure, decreas-
ing the immunosuppressive influence of testosterone, in
turn enhancing the ability to fight infection. Weight loss
and physical activity seem to improve these symptoms
[260]. These novel findings suggest a potential impact
for microbe therapy in obese and/or aging athletes by
imparting hormonal and gonadal features of reproduct-
ive fitness typical of much younger healthy individuals.
However, studies are severely lacking. In the future, lar-
ger sample sizes and more robust study designs will be
needed.
Inactivated “probiotics”
There is an increasing interest in supplementation with
non-viable microorganisms or microbial cell extracts. By
definition, probiotics are required to be alive, therefore
inactivated microorganisms cannot be classified as such.
However, preparations from certain probiotic speciesand strains (such as those from lactobacilli and bifido-
bacteria) have shown to maintain health benefits even
after no longer being viable [261–263]. Inactivation can
be achieved by different methods, including heat, chemi-
cals (e.g., formalin), gamma or ultraviolet rays, and son-
ication, with heat treatment being the method of choice
in most cases [228, 264, 265]. Importantly, these
methods of inactivation may affect structural compo-
nents of the cell differently, and therefore their biological
activities [264, 265]. Piqué et al. (2019) suggested the
presence of key structures in the cell or supernatant
fractions may confer probiotic properties, mainly
through immune-modulation, protection against path-
ogens, and fortifying the mucosal barrier integrity
[261]. These different bacterial components include
lipoteichoic acids, peptidoglycans, and/or exopolysac-
charides [261].
Favorable properties of heat-killed bacteria have been
observed in vitro [266], in animal models [264], and hu-
man trials [267, 268]. For example, in healthy subjects
with high levels of self-reported psychological stress,
supplementation with heat-killed L. plantarum L-137
significantly lowered incidence of URTI after 12 weeks
compared to the control group [269]. This finding may
have resulted from innate immunity stimulation as heat-
killed L. plantarum L-137 has been reported to enhance
type I IFN production in humans [270]. In athletes, there
have only been two studies published examining the ef-
fect of these inactivated “probiotics”. In a randomized,
double blind, placebo-controlled trial, 51 male athletes
engaged in high intensity exercise (> 11 h per week) and
consumed a placebo or heat-killed L. lactis JCM 5805
daily for 13 days [262]. Compared to placebo, supple-
mentation increased the maturation marker of plasmacy-
toid DC pDC (CD86), responsible for the antiviral
response, and decreased the cumulative days of URTI
symptoms. Furthermore, ingestion decreased cumulative
days of self-reported fatigue. In a longer duration ran-
domized, double blind, placebo-controlled study, 49
long-distance runners consumed heat-inactivated L. gas-
seri CP2305 or placebo daily for 12 weeks [271]. No sig-
nificant difference in physical performance between the
CP2305 and placebo group were detected. However,
CP2305 supplementation improved recovery from fa-
tigue and relieved anxiety and depressive mood com-
pared with placebo intake. Further, CP2305 intake
prevented training-induced reduction of hemoglobin and
facilitated exercise-induced increase in serum growth
hormone levels. Moreover, gene expression profiling of
peripheral blood leukocytes indicated that CP2305
prevented the stress-induced changes in the expression
of genes related to mitochondrial functions. In relation
to the gut microbiota, CP2305 intake increased the
alpha- and beta-diversity, and the compositions of
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itional changes in the gut microbiota may have contrib-
uted to the recovery of fatigue and moderation of stress
and anxiety through the gut-brain axis. Indeed, inacti-
vated CP2305 can relieve stress in healthy young adults
facing stressful conditions [272]. While encouraging, it is
unclear how the daily intake of the heat-inactivated pro-
biotics could affect the gut-brain axis and alter stress re-
sponses. Further research investigating potential
mechanisms as well as more extensive studies with a
wider range of athletes and exercise loads should be
conducted. In addition, primary aims related to GI tract
health and exercise performance should be more thor-
oughly assessed.
Mood and cognition
Physical health and mental health are strongly linked with
depression, which is recognized as a leading cause of
disability throughout the world [273]. Recently, it has
been reported that 35% of individuals with depression also
have symptoms of a leaky gut [274], which strengthens
the notion of a link between the brain and the GI tract. As
reported by Clarke et al. [275], gut bacteria contribute to
various mood states in an individual. The gut-brain axis is
a bidirectional pathway via the neural, endocrine, and im-
mune systems. The mechanisms by which probiotics im-
prove symptoms of depression and other mood disorders
are via anti-inflammatory actions that reduce activity of
the hypothalamic-pituitary-adrenal (HPA) axis [276].
Probiotics may be an effective treatment strategy for
depression and mood disorders such as anxiety given the
link between GI tract bacteria and the brain (i.e. the gut-
brain axis), as decreased intestinal dysbiosis may have bene-
ficial effects on mood. Only a few studies have been com-
pleted in human subjects that have examined the impact of
probiotic supplementation on mood and anxiety. Benton
and colleagues [210] reported that 3 weeks of supplementa-
tion with 1 × 108 CFU of L. casei had positive effects on
mood, with subjects feeling increased clear-headedness,
confidence, and elation compared to baseline. A study by
Rao et al. [277], reported that 8 weeks of 8 × 107 CFU of L.
casei given to individuals with chronic fatigue syndrome re-
duced anxiety symptoms. Similarly, Messaoudi and others
[278] found decreased anxiety related behaviors after 2
weeks of a combination of L. helveticus and B. longum in
25 healthy adults. Moreover, 6 weeks supplementation of
4 × 109 CFU/live cells of L. fermementum LF16, L. rhamno-
sus LR06, L. plantarum LP01, and B. longum BL04 im-
proved mood and sleep quality with a reduction in
depressive mood state, anger and fatigue [279].
Overall, research on probiotics and mood in athletic
populations is lacking. One review, completed by Clark
and Mach [280] likened the psychological demands of
exercise to physical stress. These authors concluded thatthe gut microbiota acts as an endocrine organ, secreting
neurotransmitters such as serotonin and dopamine,
thereby controlling the hypothalamic-pituitary axis in ath-
letes. It is unclear whether these conclusions are attribut-
able to the physiological or psychological stress, and more
research is needed to expand on the current findings.
Muscle damage and recovery
Inflammation has been implicated in probiotic
supplementation impacting body fat levels in overweight
and obese individuals, as well as athletic populations.
Research in this area, however, has been completed
entirely in animal models. Zhao et al. [281] reported that
supplementation of Akkermancia muciniphila in lean
mice fed a chow diet for 5 weeks significantly improved
markers of low-grade, chronic inflammation via measure-
ment of LPS, and alleviated gains in both body weight and
fat mass. Probiotic supplementation also increased anti-
inflammatory factors α-tocopherol and β-sitosterol. Inter-
action between A. muciniphila and inflammatory pro-
cesses may subsequently impact metabolic health and
consequently body composition regulation. In humans,
low-grade, chronic inflammation is a marker of many dis-
ease states and aspects of the metabolic syndrome. To
date, no such research has been completed in athletic pop-
ulations to clarify the impact of probiotic supplementation
on body composition in athletes.
Neurotransmitter synthesis and release
Choline and its derivatives serve as components of
structural lipoproteins, blood and membrane lipids, and as
a precursor of the neurotransmitter, acetylcholine [282].
Choline is converted into acetylcholine via the enzyme
choline acetyltransferase. Increasing plasma levels of
choline could improve the production of acetylcholine,
increase muscular contraction, and possibly delay fatigue in
endurance exercise [282]. Elevated choline levels were
observed in plasma of mice supplemented with L.
rhamnosus compared to those fed with L. paracasei and
controls [283]. In humans, probiotics and choline have
been studied in the context of Trimethylamine N-oxide
(TMAO). TMAO is an atherogenic metabolite that requires
gut microbes for its generation through a metaorganismal
pathway that begins with dietary consumption of trimethy-
lamine (TMA) containing precursors such as choline, carni-
tine and phosphatidylcholine [284]. In a two-week clinical
study on 19 healthy, non-obese males, supplementing with
a multi-strain probiotic following a hypercaloric, high-fat
diet failed to elevate plasma choline levels [285]. In a three-
month pilot study investigating the effects of probiotic sup-
plementation on TMAO plasma levels in hemodialysis pa-
tients, choline did not change compared to control group
[286]. There is currently no research in athletes or active in-
dividuals, yet increases in plasma choline could (in theory)
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and endurance.Nutrient timing
As indicated previously, various supplementation
protocols have been implemented regarding probiotic
consumption supplementation, including taking on an
empty stomach, with food, and even after exercise. In
relation, little is known pertaining to the optimal
timing of probiotic intake for improved microbial
survival and nutrient absorption. Tompkins et al.
utilized an in vitro digestive model of the upper GI
tract to investigate the timing effects of probiotic
intake utilizing a multi-species encapsulated product
containing L. helveticus R0052, L. rhamnosus R0011,
B. longum R0175, and S. cerevisiae boulardii [287].
Results of this investigation showed that when a pro-
biotic was consumed 30 min before a meal or with a
meal, the bacteria survived in high numbers. Con-
versely, when the probiotic was taken 30 min after a
meal, the bacteria did not survive in high numbers.
Additionally, this study reported that consumption of
the probiotic with 1% milk and oatmeal-milk gruel
allowed for higher bacteria survival than when con-
sumed with apple juice or spring water. Thus, future
work should focus on the most favorable time to con-
sume probiotics to promote survival in humans along
with optimal nutrient/foodstuffs co-ingestion.Response to a physical or mental stressor
Cortisol is a steroid hormone released by the adrenal
glands in response to stress and increased levels have been
related to suppression of the immune system in athletes
[288–290]. Moreover, a connection has been established
between the digestive tract and stress [291, 292]. Several
studies that supplemented healthy young college students
during exam preparation with probiotics (L. plantarum
299v and L. casei Shirota) reported attenuation of cortisol
compared to a control group [293–295]. However, in an
eight-week crossover design, 29 healthy male volunteers
who supplemented with L. rhamnosus exhibited little dif-
ference in stress-related measures, HPA axis response, in-
flammation, or cognitive performance in comparison to
placebo [296]. More recently, a systematic review and
meta-analysis of clinical and pre-clinical literature on the
effects of probiotics on anxiety asserted that probiotics
may help reduce anxiety [297]. However, these findings
have not yet been fully translated in clinical research in
humans. More relevant to performance, eight endurance-
trained males in a blinded randomized crossover design
who supplemented with a probiotic beverage (L. casei, 1 ×
1011 CFU) for seven consecutive days before a two-hour
running exercise at 60% VO2max in hot ambientconditions (34.0 °C and 32% RH) failed to exhibit a de-
crease in cortisol response compared to a placebo [75].
Key Points 8 – Future Directions
• Probiotic therapy has the potential to positively affect the endocrine
system (testosterone production), especially for obese and/or aging
athletes.
• Modulation of the gut microbiome could alter the production/level
of important neurotransmitters related to athletic performance.
• Probiotic supplementation may have an impact on stress; however,
current research is limited.
• Preliminary animal research suggests probiotic supplementation may
support the removal and utilization of blood lactate.
• Important methodological considerations must be addressed
systematically in future research including the effect of: sex, sample
size, duration, dose (type and amount), level of physical activity, and
type of exercise.Summary
Understanding whether probiotic supplementation plays
a role in athletic performance is of interest to athletes
who work to improve their training and competition
performance. Moreover, this knowledge may be of
general benefit to human health. Further studies are
required to understand how the microbiome influences
anti-inflammatory effects, optimal breakdown and
utilization of consumed food, and other beneficial effects
for overall health in athletes. Overall, the studies
reviewed in this position statement provide modest evi-
dence that probiotics can provide some clinical benefits
in athletes and other highly active individuals (Table 3).
The difficulty in interpreting the studies is illustrated by
variations in clinical outcome measures and most im-
portantly, as probiotic benefits are strain-specific, by dif-
ferent strains used in these studies.
As outlined in Table 3, the following probiotic strains/
species have been linked to an increase in athletic
performance and/or recovery:
1) B. coagulans GBI-30, 6086 (BC30) at 1 × 109 CFU
has beneficial effects in combination with protein
on exercise recovery;
2) Encapsulated B. breve BR03 in combination with S.
thermophilus FP4 at 5 × 109 CFU each has
beneficial effects on exercise recovery and
performance following muscle-damaging exercise;
3) L. delbrueckii ssp. bulgaricus at 1 × 105 CFU can
increase VO2max and aerobic power;
4) L. acidophilus SPP, L. delbrueckii bulgaricus, B.
bifidum, and S. salivarus thermophilus at 4 × 1010
CFU administered in form of a yogurt drink can
increase VO2max;
5) L. plantarum TWK10 at 1 × 1010 CFU has been
shown to increase endurance performance;
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L. fermentum, B. lactis, B. breve, B. bifidum and S.
thermophilus at 4.5 × 1010 CFU can increase run
time to fatigue in the heat.
The following probiotic strains/species have been
linked to improved gut health in athletes (see Table 3):
1) L. rhamnosus GG at 4 × 1010 CFU in form of a
milk-based drink,
2) B. bifidum W23, B. lactis W51, E. faecium W54, L.
acidophilus W22, L. brevis W63, and L. lactis W58,
at 1 × 1010 CFU;
3) L. salivarius (UCC118) (unknown dose).
The following strains/species have been shown to
improve immune health in athletes, reducing the episodes,
severity or duration of exercise-induced infections:
1) 1.2 × 1010 CFU L. fermentum VRI-003 (PCC) at
1.2 × 1010 CFU and at 1 × 109 CFU in males;
2) L. casei Shirota (LcS) at 6.5 × 109 CFU twice daily;
3) L. delbrueckii bulgaricus, B. bifidum, and S.
salivarus thermophilus at 4 × 1010 CFU
administered in the form of a yogurt drink;
4) B. animalis subsp. lactis BI-04 2 × 1010 CFU;
5) L. gasseri 2.6 × 109 CFU, B. bifidum 0.2 × 109, and B.
longum 0.2 × 109 CFU;
6) B. bifidum W23, B. lactis W51, E. faecium W54, L.
acidophilus W22, L. brevis W63, L. lactis W58 at
1 × 1010 CFU;
7) L. helveticus Lafti L10 at 2 × 1010 CFU.
Given the small number of studies, and substantial
variation in experimental approaches, dependent
measures, and outcomes, more well-designed studies of
probiotic supplementation in various athlete groups are
warranted. While a majority of probiotics currently on
the market, and tested in humans, feature the Lactoba-
cillus, Bifidobacterium, and Bacillus genera, new micro-
biome research and technological advances are
identifying potential next-generation probiotic candi-
dates. Further research is needed not only to identify
these discoveries, and validate their performance and re-
covery benefits in clinical settings.
Recommendations
Athletes and physically active individuals should thoroughly
review health care and consumer information on specific
applications, dosage, and possible contraindications of
probiotic supplementation. As with any dietary suppleme
ntation, probiotics should be considered in the overall
context of balanced dietary intake, i.e. nutrient needs should
be met by a “food first” approach via consumption of wholefoods rather than supplements. For example, recommending
dietary supplements to developing athletes might
overemphasize their importance in comparison to other
training and dietary strategies [298]. In this context, it is also
important to remember that some food-based probiotic
products (e.g. yogurt) contain energy, carbohydrate, protein,
and other nutrients that can form part of an athlete’s overall
nutrition plan. Only reputable sources of commercially avail-
able supplements should be used to reduce the risk of con-
taminants that might contravene doping in sport regulations
[5]. Athletes should be educated on the likely risks of con-
tamination given that the World Anti-Doping Agency en-
forces a principle of strict liability for positive test results
involving banned substances. Different formulations of pro-
biotics from tablets or capsules to powder (added to drinks)
or probiotic-enriched chewable tablets are available to meet
individual preferences.
Probiotic supplements should be packaged, stored,
handled, and transported in an appropriate manner.
Athletes should take particular care in warm to hot
environments and avoid, where possible, leaving
supplements outdoors for long periods in direct sunlight,
in a motor vehicle, or near an oven or other heat-
generating appliances. New technology has led to pro-
biotic supplements that do not require refrigeration,
which may be ideal for athletes during travel. Supplements
should also be kept dry at all times. During travel it might
be useful for individuals to keep probiotics with other nu-
tritional supplies, supplements, ergogenic acids or medica-
tions, or held by team personnel as required.
In terms of implementation, probiotic supplementation
should commence at least 14 days before a major training
period or competition to allow adequate time for transient
colonization or adaptation period of bacterial species in
the gut. Another important issue is the increased risk of
GI problems during travel [299]. Supplementation with
probiotics for individuals and athletes traveling could be
included in an overall illness prevention plan. Tolerance
and side effects should be monitored by the athlete, coach,
and support staff and a medical opinion sought if there is
ongoing concern. It is not unusual to experience transient
increased activity in the gut during the colonization
period (e.g., intestinal rumbling, increased flatulence, etc.)
and athletes should be informed that mild side effects for
a few days are not uncommon [61]. Athletes should be
encouraged to review and monitor probiotic consumption
on a daily basis to promote compliance and best practice
usage. Compliance might be improved by having athletes
take the probiotic supplement at the same time each day
(e.g., at breakfast). Probiotic supplementation should be
tested during the offseason or preseason phases, so the
athlete is familiar with taking the probiotic supplements
or foods before travel or major competition, and can see
how he/she responds. This practice is also useful in the
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adverse effects.Position of the International Society of Sports Nutrition
(ISSN)
After reviewing the scientific and medical literature in this
area, the International Society of Sports Nutrition concludes
the following in terms of probiotic supplementation as the
official Position of the Society:
1) Probiotics are live microorganisms that, when
administered in adequate amounts, confer a health
benefit on the host (FAO/WHO).
2) Probiotic administration has been linked to a
multitude of health benefits, with gut and immune
health being the most researched applications.
3) Despite the existence of shared, core mechanisms
for probiotic function, health benefits of probiotics
are strain- and dose-dependent.
4) Athletes have varying gut microbiota compositions
that appear to reflect the activity level of the host in
comparison to sedentary people, with the
differences linked primarily to the volume of
exercise and amount of protein consumption.
Whether differences in gut microbiota composition
affect probiotic efficacy is unknown.
5) The main function of the gut is to digest food and
absorb nutrients. In athletic populations, certain
probiotics strains can increase absorption of key
nutrients such as amino acids from protein, and
affect the pharmacology and physiological
properties of multiple food components.
6) Immune depression in athletes worsens with
excessive training load, psychological stress,
disturbed sleep, and environmental extremes, all of
which can contribute to an increased risk of
respiratory tract infections. In certain situations,
including exposure to crowds, foreign travel and
poor hygiene at home, and training or competition
venues, athletes’ exposure to pathogens may be
elevated leading to increased rates of infections.
Approximately 70% of the immune system is
located in the gut and probiotic supplementation
has been shown to promote a healthy immune
response. In an athletic population, specific
probiotic strains can reduce the number of
episodes, severity and duration of upper respiratory
tract infections.
7) Intense, prolonged exercise, especially in the heat,
has been shown to increase gut permeability which
potentially can result in systemic toxemia. Specific
probiotic strains can improve the integrity of the
gut-barrier function in athletes.8) Administration of selected anti-inflammatory pro-
biotic strains have been linked to improved recovery
from muscle-damaging exercise.
9) The minimal effective dose and method of
administration (potency per serving, single vs. split
dose, delivery form) of a specific probiotic strain
depends on validation studies for this particular
strain. Products that contain probiotics must
include the genus, species, and strain of each live
microorganism on its label as well as the total
estimated quantity of each probiotic strain at the
end of the product’s shelf life, as measured by
colony forming units (CFU) or live cells.
10) Preclinical and early human research has shown
potential probiotic benefits relevant to an athletic
population that include improved body composition
and lean body mass, normalizing age-related de-
clines in testosterone levels, reductions in cortisol
levels indicating improved responses to a physical
or mental stressor, reduction of exercise-induced
lactate, and increased neurotransmitter synthesis,
cognition and mood. However, these potential ben-
efits require validation in more rigorous human
studies and in an athletic population.
Conclusion
Given all the known benefits and favorable safety profile of
probiotic supplementation reported in the scientific and
medical literature, probiotics are commonly used to
optimize the health of athletes. Regular consumption of
specific probiotic strains may assist with immune function
and may reduce the number of sick days an athlete
experiences when training or during competition. Certain
probiotic strains may reduce the severity of respiratory
infection and GI disturbance when they occur. Probiotic
benefits are strain specific and dose dependent, and include
improved gut-barrier function, nutrient absorption, recov-
ery and performance in athletes. When choosing a pro-
biotic product, athletes are encouraged to use clinically
researched strains with validated benefits, matching the ath-
letes desired health benefit. Studies investigating the effects
of probiotics in athletic populations and on sports perform-
ance are limited and warrant further investigation.
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